​ Forward-Looking Statements ​ In addition to historical information, this Quarterly Report on Form 10–Q contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “forecast,” “estimate,” “project,” “intend,” “plan,” “expect,” “should,” “believe” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions and speak only as of the date on which it is made. Examples of forward-looking statements include statements we make regarding future attendance levels, revenues and our liquidity. These forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors, including those discussed in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the following: ​ ● the risks and uncertainties relating to the sufficiency of our existing cash and cash equivalents and available borrowing capacity to fund operations and satisfy obligations including cash outflows for planned capital expenditures currently and through the next twelve months. Based on our current cost structure, in order to achieve annual net positive cash flows from operating activities, revenues will need to be at least in line with pre-COVID-19 revenues. However, there remain significant risks that may negatively impact revenues, costs, and attendance levels, including changes to movie studios release schedules (including as a result of production delays and delays to the release of movies caused by labor stoppages) and direct to streaming or other changing movie studio practices. If we are unable to achieve increased levels of attendance and revenues, we will be required to obtain additional liquidity. If such additional liquidity is not obtained or is insufficient, we likely would seek an in-court or out-of-court restructuring of our liabilities, and in the event of such future liquidation or bankruptcy proceeding, holders of our Common Stock and other securities would likely suffer a total loss of their investment; ● the risks and uncertainties relating to the 2025 Refinancing Transactions and 2024 Refinancing Transactions (each defined herein), including, but not limited to, (i) the potential for additional future dilution of our Common Stock as a result of issuance of shares underlying our Existing Exchangeable Notes, (ii) the possibility that the extension of certain debt maturities will not provide enough time for attendance and revenues to increase to sufficient levels and generate net positive cash flows to overcome liquidity concerns, and (iii) the impact on the market price of our Common Stock and our capital structure 31 Table of Contents of any litigation or claims of default that might arise in connection with the 2025 Refinancing Transactions or 2024 Refinancing Transactions; ● changing practices of distributors, which accelerated during the COVID-19 pandemic, including increased use of alternative film delivery methods including premium video on demand, streaming platforms, shrinking exclusive theatrical release windows or release of movies to theatrical exhibition and streaming platforms on the same date, the theatrical release of fewer movies due to industry consolidation or other reasons, or transitioning to other forms of entertainment; ● the impact of changing movie-going behavior of consumers; ● the risk that the North American and international box office in the near term will not recover sufficiently, resulting in continued cash burn and the need to seek additional financing, which may not be available at favorable terms, or at all; ● risks and uncertainties relating to our significant indebtedness, including our borrowings and our ability to meet our debt covenants; ● the dilution caused by recent and potential future sales of our Common Stock and future potential share issuances to repay, refinance, redeem or repurchase indebtedness (including expenses, accrued interest and premium, if any); ● risks relating to motion picture production, promotion, marketing, and performance, including labor stoppages affecting the production, supply and release schedule of theatrical motion picture content and choice of distributors to release fewer feature-length films as a result of the additional financial burden imposed by tariffs on motion picture production; ● the potential impact on our business resulting from consolidation among, or structural changes to, movie studios, distribution companies, or producers of other third-party media, including the uncertainty created when any such transaction is the subject of pending regulatory review, judicial proceedings, or injunctive relief, the outcome of which may materially affect the structure and dynamics of the markets in which we operate and the production and release of theatrical motion pictures; ● the use of artificial intelligence (“AI”) technology in the filmmaking process and audience acceptance of movies made utilizing AI technology; ● the seasonality of our revenue and working capital, which are dependent upon the timing of motion picture releases by distributors, such releases being seasonal and resulting in higher attendance and revenues generally during the summer months and holiday seasons, and higher working capital requirements during the other periods such as the first quarter; ● intense competition in the geographic areas in which we operate among exhibitors, streaming platforms, or from other forms of entertainment; ● certain covenants in the agreements that govern our indebtedness that limit or restrict our ability to take advantage of certain business opportunities, pay dividends, incur additional debt, pre-pay debt, and also to refinance debt and to do so at favorable terms, and such covenants that impose additional administrative and operational burdens on our business; ● risks relating to impairment losses, including with respect to goodwill and other intangibles, and theatre and other closure charges; ● general and international economic, political, regulatory, social and financial market conditions, including potential economic recession, inflation, rising interest rates, the financial stability of the banking industry, and other risks that may negatively impact discretionary income and our revenues and attendance levels; ● our lack of control over distributors of films; 32 Table of Contents ● limitations on the availability of capital or poor financial results may prevent us from deploying strategic initiatives; ● an issuance of preferred stock could dilute the voting power of the common stockholders and adversely affect the market value of our outstanding Common Stock; ● limitations on the authorized number of Common Stock shares could in the future prevent us from raising additional capital through sales of Common Stock; ● our ability to achieve expected synergies, benefits and performance from our strategic initiatives; ● our ability to refinance our indebtedness on terms favorable to us or at all; ● our ability to optimize our theatre circuit through new construction, the transformation of our existing theatres, and strategically closing underperforming theatres may be subject to delay and unanticipated costs; ● failures, unavailability or security breaches of our information systems, including due to cybersecurity incidents; ● our ability to utilize interest expense deductions will be limited annually due to Section 163(j) of the Internal Revenue Code of 1986, as amended, as amended by the One Big Beautiful Bill Act of 2025; ● our ability to recognize interest deduction carryforwards, net operating loss carryforwards and other tax attributes to reduce our future tax liability; ● our ability to recognize certain international deferred tax assets which currently do not have a valuation allowance recorded; ● review by antitrust authorities in connection with acquisition opportunities; ● risks relating to the incurrence of legal liability; ● dependence on key personnel for current and future performance and our ability to attract and retain senior executives and other key personnel, including in connection with any future acquisitions; ● increased costs in order to comply or resulting from a failure to comply with governmental regulation, including the General Data Protection Regulation and all other current and pending privacy and data regulations in the jurisdictions where we have operations; ● supply chain disruptions may negatively impact our operating results; ● the availability and/or cost of energy; ● the market price and trading volume of our shares of Common Stock has been and may continue to be volatile, and purchasers of our securities could incur substantial losses; ● future offerings of debt, which would be senior to our Common Stock for purposes of distributions or upon liquidation, could adversely affect the market price of our Common Stock; ● the potential for political, social, or economic unrest, terrorism, hostilities, cyber-attacks or war, including the conflict between Russia and Ukraine, military actions in and around Iran, and other international conflicts; ● the potential impact of financial and economic sanctions on the regional and global economy, or widespread health emergencies, such as pandemics or epidemics, causing people to avoid our theatres or other public places where large crowds are in attendance; 33 Table of Contents ● anti-takeover protections in our Fourth Amended and Restated Certificate of Incorporation and our Fourth Amended and Restated Bylaws may discourage or prevent a takeover of our Company, even if an acquisition would be beneficial to our stockholders; and ● other risks and uncertainties referenced from time to time in filings with the Securities and Exchange Commission (“SEC”). This list of factors that may affect future performance and the accuracy of forward-looking statements is illustrative but not exhaustive. In addition, new risks and uncertainties may arise from time to time. Accordingly, all forward-looking statements should be evaluated with an understanding of their inherent uncertainty and we caution accordingly against relying on forward-looking statements. Except as required by law, we assume no obligation to publicly update or revise these forward-looking statements for any reason. Actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Readers are urged to consider these factors carefully in evaluating the forward-looking statements. For further information about these and other risks and uncertainties as well as strategic initiatives, see “Item 1A. Risk Factors” of this Form 10-Q, “Item 1. Business” in our Annual Report on Form 10–K for the year ended December 31, 2025, and our other public filings. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. The forward-looking statements included herein are made only as of the date of this Quarterly Report on Form 10–Q, and we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Overview AMC is the world’s largest theatrical exhibition company and an industry leader in innovation and operational excellence. As of June 30, 2026, we operated theatres in 11 countries, including the United States, and various countries throughout Europe. Our theatrical exhibition revenues are generated primarily from box office admissions and food and beverage sales. The balance of our revenues is generated from ancillary sources, including online ticketing fees, on-screen advertising, income from gift card and exchange ticket sales, rental of theatre auditoriums, retail popcorn and merchandise sales, fees earned from our customer loyalty programs, and theatrical distribution. As of June 30, 2026, we owned, operated or had interests in 845 theatres and 9,530 screens. Box Office Admissions and Film Content Box office admissions are our largest source of revenue. We predominantly license theatrical films from distributors owned by major film production companies and from independent distributors on a film-by-film and theatre-by-theatre basis. Film exhibition costs are based on a share of admissions revenues and are accrued based on estimates of the final settlement pursuant to our film licenses. These licenses typically state that rental fees are based on the box office performance of each film, though in certain circumstances and less frequently, our rental fees are based on a mutually agreed settlement rate that is fixed. In some European territories, film rental fees are established on a weekly basis and some licenses use a per capita agreement instead of a revenue share, paying a flat amount per ticket. Our revenues attributable to individual distributors may vary significantly from year to year depending upon the commercial success of each distributor’s films in any given year. Our results of operations may vary significantly from quarter to quarter and from year to year based on the timing and popularity of film releases. 34 Table of Contents Movie Screens ​ The following table provides detail with respect to Premium Large Format (“PLF”) screens (IMAX®, Dolby CinemaTM, SCREENX, 4DX, in-house), XL screens, 3D enabled screens, premium seating, and our enhanced food and beverage offerings as deployed throughout our circuit as of June 30, 2026 and June 30, 2025: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ U.S. Markets ​ International Markets ​ Consolidated ​ ​ As of June 30, ​ As of June 30, ​ As of June 30, Format ​ 2026 ​ 2025 ​ 2026 ​ 2025 ​ 2026 ​ 2025 Number of theatres: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ IMAX® 186 182 ​ 39 35 ​ 225 ​ 217 Dolby Cinema™ theatres 175 167 ​ 7 7 ​ 182 ​ 174 In-house PLF 74 63 ​ 80 79 ​ 154 ​ 142 Dine-in 22 48 ​ 3 3 ​ 25 ​ 51 Premium seating ​ 368 ​ 366 ​ 90 ​ 88 ​ 458 ​ 454 XL screens ​ 58 10 ​ 74 72 ​ 132 82 SCREENX ​ 5 ​ — ​ 6 ​ 6 ​ 11 ​ 6 4DX ​ 3 ​ — ​ — ​ — ​ 3 ​ — 3D enabled ​ 514 ​ 528 ​ 247 ​ 262 ​ 761 ​ 790 Number of screens: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ IMAX® ​ 187 ​ 183 ​ 39 ​ 35 ​ 226 ​ 218 Dolby Cinema™ theatres ​ 175 ​ 167 ​ 7 ​ 7 ​ 182 ​ 174 In-house PLF ​ 78 ​ 67 ​ 83 ​ 82 ​ 161 ​ 149 Dine-in ​ 226 ​ 666 ​ 13 ​ 13 ​ 239 ​ 679 Premium seating ​ 3,648 ​ 3,641 ​ 651 ​ 618 ​ 4,299 ​ 4,259 XL screens ​ 102 ​ 19 ​ 91 ​ 85 ​ 193 ​ 104 SCREENX ​ 5 ​ — ​ 6 ​ 6 ​ 11 ​ 6 4DX ​ 3 ​ — ​ — ​ — ​ 3 ​ — 3D enabled ​ 2,756 ​ 2,827 ​ 913 ​ 1,042 ​ 3,669 ​ 3,869 ​ Loyalty Programs and Other Marketing ​ As of June 30, 2026, we had a combined total of approximately 40.7 million member households enrolled in our AMC Stubs® A-List, AMC Stubs Premiere™, AMC Stubs Premiere GO!, and AMC Stubs Insider™ programs (collectively, “AMC Stubs”). During the six months ended June 30, 2026, our AMC Stubs members represented approximately 51.6% of AMC U.S. markets attendance. We currently have approximately 20.8 million total members in our various International loyalty & subscription programs. See “Item 1. Business” in our Annual Report on Form 10-K for the year ended December 31, 2025 for additional discussion and information of our screens, seating concepts, amenities, loyalty programs and other marketing initiatives. Holders of Shares As of June 30, 2026, there were 892,604,638 shares of our Common Stock outstanding. Of those outstanding shares, approximately 2.2 million shares (or 0.25%) were held by 13,720 registered holders with our transfer agent and approximately 890.4 million (or 99.75%) were held by Cede & Co on behalf of the Depository Trust & Clearing Corporation, commonly referred to as held in “street name” for beneficial holders owning shares through bank or brokerage accounts. 35 Table of Contents Critical Accounting Estimates For a discussion of our critical accounting policies and the means by which we develop estimates, see “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2025. Significant Events—For the Six Months Ended June 30, 2026 Odeon Credit Agreement. On April 17, 2026, Odeon Finco, a wholly-owned direct subsidiary of OCGL and an indirect subsidiary of Holdings, entered into the Odeon Credit Agreement, by and among Odeon Finco, as borrower, OCGL, as the company, the lenders party thereto and U.S. Bank Trust Company, National Association, as administrative agent and security agent, pursuant to which Odeon Finco borrowed $425.0 million of Odeon Term Loans due 2031. The Odeon Term Loans due 2031 bear interest at a fixed 10.50% interest rate and are subject to amortization of principal, payable in quarterly installments on the fifteenth day of each April, July, October, and January (commencing July 15, 2026), equal to 1.00% per annum. The proceeds from the Odeon Term Loans due 2031 and approximately $38.2 million of cash from the balance sheet were used to fund the Odeon Notes Redemption of Odeon Finco’s outstanding Odeon Notes due 2027 and to pay related fees, costs, premiums and expenses, including approximately $23.5 million of interest due on the Odeon Notes due 2027. In connection with the Odeon Notes Redemption, the Odeon Notes due 2027 have been delisted from the Official List of The International Stock Exchange. We treated the Odeon Notes Redemption as an extinguishment of debt and recorded a $30.1 million loss on extinguishment. See Note 5—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for further information. New Exchangeable Notes Voluntary Exchange. On May 4 and May 11, 2026, the Exchanging Noteholders delivered Notices of Voluntary Exchange to Muvico and GLAS Trust Company LLC, as exchange agent, to exchange all $155,845,562 aggregate principal amount of New Exchangeable Notes outstanding for shares of Common Stock, pursuant to the terms of the Indenture. The Company settled the Exchange by issuing an aggregate of 142,102,295 shares of Common Stock to the Exchanging Noteholders (including shares issued in respect of the Exchange Adjustment Consideration (as defined in the Indenture) and accrued and unpaid interest). We treated the Exchange as an extinguishment of the New Exchangeable Notes (including the bifurcated embedded derivative liability for the embedded conversion features) and recorded a loss on extinguishment of $33.0 million. We adjusted the bifurcated embedded derivative liability to fair value immediately prior to the Exchange and recorded $41.3 million of expense during the three months ended June 30, 2026. During the six months ended June 30, 2026, we recorded $(11.1) million of other income related to the decrease in the fair value of the bifurcated embedded derivative liability. As a result of the Exchange, all remaining New Exchangeable Notes were cancelled in accordance with the Indenture. Share Issuances. In June 2026, we entered into the Purchase Agreement with the Investors for the sale of 95,250,000 shares of Common Stock in the Offering, at a purchase price of $2.10 per share. The Offering closed on June 24, 2026. In connection with the Offering, we entered into the Placement Agency Agreement with the Placement Agent, as exclusive placement agent in connection with the Offering. As compensation to the Placement Agent, the Company will pay the Placement Agent a cash fee of 5.5% of the aggregate gross proceeds raised in the Offering and will reimburse certain expenses. We will use the proceeds from the Offering to redeem the Senior Subordinated Notes due 2027, pay related fees, costs, premiums and expenses associated therewith and for general corporate purposes, which may include the repayment of other debt, the strengthening of our cash reserves and investments to enhance the moviegoing experience at our theatres. 36 Table of Contents The below table summarizes activity during the six months ended June 30, 2026 related to the Offering: ​ ​ ​ ​ ​ ​ Six Months Ended (In millions) ​ June 30, 2026 Shares issued direct offering ​ ​ 95.3 Direct offering gross proceeds ​ $ 200.0 Placement fees paid ​ $ 11.0 Other third-party issuance costs incurred ​ $ 0.2 Other third-party issuance costs paid ​ $ 0.2 ​ During the six months ended June 30, 2026, we issued shares through an “at-the-market offering”. The below table summarizes the activity of the “at-the-market” offering. ​ ​ ​ ​ ​ ​ Six Months Ended (In millions) ​ June 30, 2026 Shares issued through at-the-market offering ​ ​ 105.3 At-the-market offering gross proceeds ​ $ 150.0 Sales agent fees paid ​ $ 3.0 Other third-party issuance costs incurred ​ $ 1.9 Other third-party issuance costs paid ​ $ 1.2 ​ See Note 6—Stockholders’ Deficit in the Notes to the Condensed Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q for further information on the share issuances. Hycroft. On February 5, 2026, the Company exercised its remaining warrants to purchase 1,000,824 common shares of Hycroft on a cashless basis and received 765,440 common shares of Hycroft. During the six months ended June 30, 2026, we sold 700,000 common shares of Hycroft for $29.7 million. As of June 30, 2026, we held 129,478 remaining common shares of Hycroft. We recorded realized and unrealized gains related to our investments in Hycroft in investment income of $(16.5) million during the six months ended June 30, 2026. Significant Events—For the Six Months Ended June 30, 2025 NCM ESA Amendment. On April 17, 2025, NCM entered into the Amended ESA with the Company. The term of the Amended ESA has been extended by five years through February 13, 2042. The Amended ESA was treated as a contract modification pursuant to ASC 606 – Revenue from Contracts with Customers. Accordingly, we have allocated the additional consideration from the contract modification to the exhibitor services agreement contract liability and updated the discount rate used to account for the significant financing component to 16.12%. Prior to the contract modification, the weighted average discount rate used to account for the significant financing component was approximately 7.5%. The contract liability will be reclassified to other theatre revenue over the new term of the Amended ESA as the remaining performance obligations are satisfied. Concurrently with entering into the Amended ESA, NCM and the Company reached an agreement to, among other things, dismiss with prejudice the ongoing litigation between the parties. Share Issuances. During the six months ended June 30, 2025, we were paid $108.7 million as initial gross cash proceeds associated with the establishment of forward positions for 30.0 million shares of Common Stock. Additionally, during the six months ended June 30, 2025, we issued shares through an “at-the-market offering.” The below table summarizes the activity of the “at-the-market” offering during the six months ended June 30, 2025: ​ ​ ​ ​ (In millions) ​ June 30, 2025 Shares issued through at-the-market offering ​ ​ 17.1 At-the-market offering gross proceeds ​ $ 63.0 Sales agent fees paid ​ $ 0.6 Other third-party issuance costs incurred ​ $ 0.3 Other third-party issuance costs paid ​ $ 1.5 ​ See Note 6—Stockholders’ Deficit in the Notes to the Condensed Consolidated Financial Statements in Part I, 37 Table of Contents Item 1 of this Form 10-Q for further information on the share issuances. 38 Table of Contents Operating Results ​ The following table sets forth our consolidated revenues, operating costs and expenses: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ ​ ​ ​ ​ ​ Six Months Ended ​ ​ ​ ​ (In millions) ​ June 30, 2026 ​ ​ ​ June 30, 2025 ​ ​ ​ % Change ​ June 30, 2026 ​ ​ ​ June 30, 2025 ​ % Change ​ Revenues ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Admissions ​ $ 863.1 ​ $ 762.6 ​ 13.2 % $ 1,441.5 ​ $ 1,236.1 ​ 16.6 % Food and beverage ​ 576.1 ​ 499.6 ​ 15.3 % 923.4 ​ 783.0 ​ 17.9 % Other theatre ​ 157.5 ​ 135.7 ​ 16.1 % 277.2 ​ 241.3 ​ 14.9 % Total revenues ​ ​ 1,596.7 ​ ​ 1,397.9 ​ 14.2 % ​ 2,642.1 ​ ​ 2,260.4 ​ 16.9 % Operating Costs and Expenses ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Film exhibition costs ​ ​ 440.3 ​ ​ 392.1 ​ 12.3 % ​ 695.9 ​ ​ 596.9 ​ 16.6 % Food and beverage costs ​ 107.7 ​ 96.1 ​ 12.1 % 174.1 ​ 153.3 ​ 13.6 % Operating expense, excluding depreciation and amortization below ​ 458.4 ​ 458.4 ​ 0.0 % 865.7 ​ 851.6 ​ 1.7 % Rent ​ 223.8 ​ 222.6 ​ 0.5 % 447.9 ​ 440.7 ​ 1.6 % General and administrative: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Merger, acquisition and other costs ​ 0.3 ​ 0.1 ​ * % 1.4 ​ 3.1 ​ (54.8) % Other, excluding depreciation and amortization below ​ 52.0 ​ 58.2 ​ (10.7) % 112.9 ​ 114.2 ​ (1.1) % Depreciation and amortization ​ 76.1 ​ 77.8 ​ (2.2) % 151.8 ​ 153.9 ​ (1.4) % Operating costs and expenses ​ 1,358.6 ​ 1,305.3 ​ 4.1 % 2,449.7 ​ 2,313.7 ​ 5.9 % Operating income (loss) ​ 238.1 ​ 92.6 ​ * % 192.4 ​ (53.3) ​ * % Other expense, net: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other expense (income) ​ 109.6 ​ (32.1) ​ * % 57.2 ​ (90.9) ​ * % Interest expense: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Corporate borrowings ​ 115.9 ​ 109.6 ​ 5.7 % 235.8 ​ 218.6 ​ 7.9 % Finance lease obligations ​ 1.7 ​ 1.4 ​ 21.4 % 3.2 ​ 2.6 ​ 23.1 % Non-cash NCM exhibitor service agreement ​ ​ 18.4 ​ ​ 18.6 ​ (1.1) % ​ 36.9 ​ ​ 27.5 ​ 34.2 % Investment expense (income) ​ 0.5 ​ (1.4) ​ * % (17.8) ​ (7.1) ​ * % Total other expense, net ​ 246.1 ​ 96.1 ​ * % 315.3 ​ 150.7 ​ * % Loss before income taxes ​ (8.0) ​ (3.5) ​ * % (122.9) ​ (204.0) ​ (39.8) % Income tax provision ​ 3.4 ​ 1.2 ​ * % 5.6 ​ 2.8 ​ 100.0 % Net loss ​ $ (11.4) ​ $ (4.7) ​ * % $ (128.5) ​ $ (206.8) ​ (37.9) % ​ * Percentage change in excess of 100% ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ ​ Six Months Ended Operating Data: ​ June 30, 2026 ​ June 30, 2025 ​ June 30, 2026 ​ June 30, 2025 Screen acquisitions — 25 8 25 Screen dispositions 66 21 100 101 Screen construction (closures), net (11) (12) (18) (5) Average screens (1) 9,249 9,402 9,280 9,416 Number of screens operated ​ 9,530 ​ 9,717 ​ 9,530 ​ 9,717 Number of theatres operated ​ 845 ​ 864 ​ 845 ​ 864 Screens per theatre 11.3 11.2 11.3 11.2 Attendance (in thousands) (1) 71,290 62,807 118,912 104,710 ​ (1) Includes consolidated theatres only and excludes screens offline due to construction. 39 Table of Contents Segment Operating Results ​ The following table sets forth our revenues, operating costs and expenses by reportable segment: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ U.S. Markets ​ International Markets ​ Consolidated ​ ​ Three Months Ended ​ Three Months Ended ​ Three Months Ended ​ ​ June 30, ​ June 30, ​ June 30, (In millions) ​ 2026 ​ 2025 ​ 2026 ​ 2025 ​ 2026 ​ 2025 Revenues ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Admissions ​ $ 667.1 ​ $ 598.7 ​ $ 196.0 ​ $ 163.9 ​ $ 863.1 ​ $ 762.6 Food and beverage ​ 470.0 ​ 411.4 ​ 106.1 ​ 88.2 ​ 576.1 ​ 499.6 Other theatre ​ 121.5 ​ 104.1 ​ 36.0 ​ 31.6 ​ 157.5 ​ 135.7 Total revenues ​ ​ 1,258.6 ​ ​ 1,114.2 ​ ​ 338.1 ​ ​ 283.7 ​ ​ 1,596.7 ​ ​ 1,397.9 Operating Costs and Expenses ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Film exhibition costs ​ ​ 362.0 ​ ​ 325.6 ​ ​ 78.3 ​ ​ 66.5 ​ ​ 440.3 ​ ​ 392.1 Food and beverage costs ​ 79.7 ​ 72.8 ​ 28.0 ​ 23.3 ​ 107.7 ​ 96.1 Operating expense, excluding depreciation and amortization below ​ 345.2 ​ 343.1 ​ 113.2 ​ 115.3 ​ 458.4 ​ 458.4 Rent ​ 161.6 ​ 162.7 ​ 62.2 ​ 59.9 ​ 223.8 ​ 222.6 General and administrative expense: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Merger, acquisition and other costs ​ 0.3 ​ 0.1 ​ — ​ — ​ 0.3 ​ 0.1 Other, excluding depreciation and amortization below ​ 28.9 ​ 34.9 ​ 23.1 ​ 23.3 ​ 52.0 ​ 58.2 Depreciation and amortization ​ 57.3 ​ 59.1 ​ 18.8 ​ 18.7 ​ 76.1 ​ 77.8 Operating costs and expenses ​ 1,035.0 ​ 998.3 ​ 323.6 ​ 307.0 ​ 1,358.6 ​ 1,305.3 Operating income (loss) ​ 223.6 ​ 115.9 ​ 14.5 ​ (23.3) ​ 238.1 ​ 92.6 Other expense (income), net: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other expense (income) ​ 81.3 ​ 2.3 ​ 28.3 ​ (34.4) ​ 109.6 ​ (32.1) Interest expense: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Corporate borrowings ​ 102.9 ​ 94.4 ​ 13.0 ​ 15.2 ​ 115.9 ​ 109.6 Finance lease obligations ​ — ​ — ​ 1.7 ​ 1.4 ​ 1.7 ​ 1.4 Non-cash NCM exhibitor service agreement ​ ​ 18.4 ​ ​ 18.6 ​ ​ — ​ ​ — ​ ​ 18.4 ​ ​ 18.6 Investment expense (income) ​ 0.8 ​ (1.4) ​ (0.3) ​ — ​ 0.5 ​ (1.4) Total other expense (income), net ​ 203.4 ​ 113.9 ​ 42.7 ​ (17.8) ​ 246.1 ​ 96.1 Earnings (loss) before income taxes ​ 20.2 ​ 2.0 ​ (28.2) ​ (5.5) ​ (8.0) ​ (3.5) Income tax provision ​ 1.7 ​ 0.5 ​ 1.7 ​ 0.7 ​ 3.4 ​ 1.2 Net earnings (loss) ​ $ 18.5 ​ $ 1.5 ​ $ (29.9) ​ $ (6.2) ​ $ (11.4) ​ $ (4.7) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ U.S. Markets ​ International Markets ​ Consolidated ​ ​ Three Months Ended ​ Three Months Ended ​ Three Months Ended ​ ​ June 30, ​ June 30, ​ June 30, Segment Operating Data: ​ 2026 ​ 2025 ​ 2026 ​ 2025 ​ 2026 ​ 2025 Screen acquisitions — 16 ​ — ​ 9 ​ — ​ 25 Screen dispositions 57 8 ​ 9 ​ 13 ​ 66 ​ 21 Screen construction (closures), net (11) (12) ​ — ​ — ​ (11) ​ (12) Average screens (1) 6,933 7,077 ​ 2,316 ​ 2,325 ​ 9,249 ​ 9,402 Number of screens operated ​ 6,958 ​ 7,131 ​ 2,572 ​ 2,586 ​ 9,530 ​ 9,717 Number of theatres operated ​ 524 ​ 540 ​ 321 ​ 324 ​ 845 ​ 864 Screens per theatre 13.3 13.2 ​ 8.0 ​ 8.0 ​ 11.3 ​ 11.2 Attendance (in thousands) (1) 52,529 46,889 ​ 18,761 ​ 15,918 ​ 71,290 ​ 62,807 ​ (1) Includes consolidated theatres only and excludes screens offline due to construction. ​ ​ 40 Table of Contents ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ U.S. Markets ​ International Markets ​ Consolidated ​ ​ Six Months Ended ​ Six Months Ended ​ Six Months Ended ​ ​ June 30, ​ June 30, ​ June 30, (In millions) ​ 2026 ​ 2025 ​ 2026 ​ 2025 ​ 2026 ​ 2025 Revenues ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Admissions ​ $ 1,063.7 ​ $ 929.8 ​ $ 377.8 ​ $ 306.3 ​ $ 1,441.5 ​ $ 1,236.1 Food and beverage ​ 729.0 ​ 628.6 ​ 194.4 ​ 154.4 ​ 923.4 ​ 783.0 Other theatre ​ 206.7 ​ 172.8 ​ 70.5 ​ 68.5 ​ 277.2 ​ 241.3 Total revenues ​ ​ 1,999.4 ​ ​ 1,731.2 ​ ​ 642.7 ​ ​ 529.2 ​ ​ 2,642.1 ​ ​ 2,260.4 Operating Costs and Expenses ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Film exhibition costs ​ ​ 548.6 ​ ​ 476.8 ​ ​ 147.3 ​ ​ 120.1 ​ ​ 695.9 ​ ​ 596.9 Food and beverage costs ​ 124.0 ​ 113.8 ​ 50.1 ​ 39.5 ​ 174.1 ​ 153.3 Operating expense, excluding depreciation and amortization below ​ 637.3 ​ 631.5 ​ 228.4 ​ 220.1 ​ 865.7 ​ 851.6 Rent ​ 324.0 ​ 325.3 ​ 123.9 ​ 115.4 ​ 447.9 ​ 440.7 General and administrative expense: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Merger, acquisition and other costs ​ 1.2 ​ 3.1 ​ 0.2 ​ — ​ 1.4 ​ 3.1 Other, excluding depreciation and amortization below ​ 67.8 ​ 72.6 ​ 45.1 ​ 41.6 ​ 112.9 ​ 114.2 Depreciation and amortization ​ 114.4 ​ 117.9 ​ 37.4 ​ 36.0 ​ 151.8 ​ 153.9 Operating costs and expenses ​ 1,817.3 ​ 1,741.0 ​ 632.4 ​ 572.7 ​ 2,449.7 ​ 2,313.7 Operating income (loss) ​ 182.1 ​ (9.8) ​ 10.3 ​ (43.5) ​ 192.4 ​ (53.3) Other expense (income), net: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other expense (income) ​ 19.8 ​ (43.1) ​ 37.4 ​ (47.8) ​ 57.2 ​ (90.9) Interest expense: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Corporate borrowings ​ 207.3 ​ 188.2 ​ 28.5 ​ 30.4 ​ 235.8 ​ 218.6 Finance lease obligations ​ — ​ — ​ 3.2 ​ 2.6 ​ 3.2 ​ 2.6 Non-cash NCM exhibitor service agreement ​ ​ 36.9 ​ ​ 27.5 ​ ​ — ​ ​ — ​ ​ 36.9 ​ ​ 27.5 Investment income ​ (17.4) ​ (6.9) ​ (0.4) ​ (0.2) ​ (17.8) ​ (7.1) Total other expense (income), net ​ 246.6 ​ 165.7 ​ 68.7 ​ (15.0) ​ 315.3 ​ 150.7 Loss before income taxes ​ (64.5) ​ (175.5) ​ (58.4) ​ (28.5) ​ (122.9) ​ (204.0) Income tax provision ​ 2.2 ​ 1.4 ​ 3.4 ​ 1.4 ​ 5.6 ​ 2.8 Net loss ​ $ (66.7) ​ $ (176.9) ​ $ (61.8) ​ $ (29.9) ​ $ (128.5) ​ $ (206.8) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ U.S. Markets ​ International Markets ​ Consolidated ​ ​ Six Months Ended ​ Six Months Ended ​ Six Months Ended ​ ​ June 30, ​ June 30, ​ June 30, Segment Operating Data: ​ 2026 ​ 2025 ​ 2026 ​ 2025 ​ 2026 ​ 2025 Screen acquisitions — 16 ​ 8 ​ 9 ​ 8 ​ 25 Screen dispositions 83 53 ​ 17 ​ 48 ​ 100 ​ 101 Screen construction openings (closures), net (31) (17) ​ 13 ​ 12 ​ (18) ​ (5) Average screens (1) 6,963 7,090 ​ 2,317 ​ 2,326 ​ 9,280 ​ 9,416 Number of screens operated ​ 6,958 ​ 7,131 ​ 2,572 ​ 2,586 ​ 9,530 ​ 9,717 Number of theatres operated 524 540 ​ 321 ​ 324 ​ 845 ​ 864 Screens per theatre 13.3 13.2 ​ 8.0 ​ 8.0 ​ 11.3 ​ 11.2 Attendance (in thousands) (1) 83,262 73,796 ​ 35,650 ​ 30,914 ​ 118,912 ​ 104,710 ​ Segment Information Our historical results of operations for the three and six months ended June 30, 2026 and June 30, 2025, reflect the results of operations for our two theatrical exhibition reportable segments, U.S. markets and International markets. Results of Operations—For the Three Months ended June 30, 2026, Compared to the Three Months ended June 30, 2025 ​ Condensed Consolidated Results of Operations ​ Revenues. Total revenues increased $198.8 million, or 14.2%, during the three months ended June 30, 2026, 41 Table of Contents compared to the three months ended June 30, 2025. Admissions revenues increased $100.5 million, or 13.2%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to an increase in attendance of 13.5% from 62.8 million patrons to 71.3 million patrons, partially offset by a 0.2% decrease in average ticket price. The decrease in average ticket price was primarily due to decreases in attendance for 3D and IMAX screens and increased frequency for our A-list subscription members, partially offset by increases in attendance for PLF and XL screens, increased ticket prices and increases in foreign currency translation rates. Attendance increased in U.S. and International markets due to the popularity of film product compared to the prior year. Food and beverage revenues increased $76.5 million, or 15.3%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to the increase in attendance and increase in food and beverage per patron. Food and beverage per patron increased 1.6% from $7.95 to $8.08 primarily due to an increase in average prices and the percentage of guests making transactions and increases in foreign currency translation rates, partially offset by lower units per transaction by guests. Total other theatre revenues increased $21.8 million, or 16.1%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to increases in income from ticket fees due to the increase in attendance, the number of guests paying ticket fees and increases in the price of ticket fees, increases in advertising income and increases in foreign currency translation rates. Operating costs and expenses. Operating costs and expenses increased $53.3 million, or 4.1%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025. Film exhibition costs increased $48.2 million, or 12.3%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to the increase in admissions revenue due to the factors discussed above, partially offset by the decrease in film exhibition cost percentage. As a percentage of admissions revenues, film exhibition costs were 51.0% for the three months ended June 30, 2026, compared to 51.4% for the three months ended June 30, 2025. Food and beverage costs increased $11.6 million, or 12.1%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025. The increase in food and beverage costs was primarily due to the increase in food and beverage revenues due to the factors discussed above, partially offset by the decrease in food and beverage cost percentage. As a percentage of food and beverage revenues, food and beverage costs were 18.7% for the three months ended June 30, 2026, compared to 19.2% for the three months ended June 30, 2025. Operating expense was unchanged during the three months ended June 30, 2026, compared to the three months ended June 30, 2025. As a percentage of revenues, operating expense was 28.7% for the three months ended June 30, 2026, compared to 32.8% for the three months ended June 30, 2025. The decrease in operating expense as a percentage of revenues is primarily due to the operating leverage gained as attendance increases. Rent expense increased $1.2 million, or 0.5%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to increases in foreign currency translation rates, partially offset by a decrease in average screens of 1.6%. Merger, acquisition, and other costs. Merger, acquisition, and other costs were $0.3 million during the three months ended June 30, 2026, compared to $0.1 million during the three months ended June 30, 2025. Other. Other general and administrative expense decreased $6.2 million, or 10.7%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025 primarily due to decreases in legal expenses due to insurance recoveries and decreases in stock-based compensation expense, partially offset by the increase in foreign currency translation rates. Depreciation and amortization. Depreciation and amortization decreased $1.7 million, or 2.2%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to theatre closures and lower depreciation expense on theatres impaired during the year ended December 31, 2025, partially offset by increases in foreign currency translation rates. ​ Other expense (income). Other expense of $109.6 million during the three months ended June 30, 2026 was primarily due to $41.3 million of expense related to the increase in fair value of the derivative liability for the embedded derivative features in the New Exchangeable Notes, $33.0 million loss on extinguishment of the New Exchangeable Notes, $30.1 million loss on extinguishment of the Odeon Notes due 2027 and $9.8 million of expense related to the increase in fair value of the derivative liability for the embedded derivative features in the Existing Exchangeable Notes, partially offset by $(0.5) million in governmental assistance, $(4.0) million in equity in earnings related to non- 42 Table of Contents consolidated entities and $(0.4) million in foreign currency transaction gains. Other income of $(32.1) million during the three months ended June 30, 2025 was primarily due to $(23.9) million in foreign currency transaction gains, $(10.3) million of governmental assistance, and $(2.1) million of equity in earnings of non-consolidated entities, partially offset by $3.9 million of expense related to the increase in fair value of the derivative liability for the embedded conversion feature in the Existing Exchangeable Notes. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about the components of other expense (income). Interest expense. Interest expense increased $6.4 million to $136.0 million for the three months ended June 30, 2026 compared to $129.6 million during the three months ended June 30, 2025 primarily due to increased interest expense of $31.3 million on the New 2029 Notes issued on July 24, 2025 and $1.4 million on the New Exchangeable Notes issued on July 1, 2025, partially offset by declines in interest expense of $11.4 million on the Existing 7.5% Notes due to redemptions of $590.0 million aggregate principal amount on July 24, 2025, $7.8 million on the Existing Exchangeable Notes issued on July 22, 2024 due to redemptions of $337.4 million aggregate principal amount on July 24, 2025, $2.4 million on the Muvico Term Loans due to lower interest rates, $2.2 million related to the refinancing of the Odeon Notes due 2027, $1.4 million on the Second Lien Notes due to redemptions of the remaining principal balances, $0.7 million on the Senior Subordinated Notes due 2026 due to redemptions of the remaining principal balances, and $0.5 million on the Senior Subordinated Notes due 2025 due to redemptions of the remaining principal balances. See Note 5—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about our indebtedness. Investment expense (income). Investment expense was $0.5 million for the three months ended June 30, 2026, compared to investment income of $(1.4) million for the three months ended June 30, 2025. Investment income in the current year includes $1.5 million of unrealized losses on our investments in common shares in Hycroft, partially offset by interest income of $(1.0) million. Investment income in the prior year includes interest income of $(1.7) million, partially offset by $0.3 million of unrealized losses on our investments in common shares and warrants to purchase common shares in Hycroft. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about our investments in Hycroft. Income tax provision. The income tax provision was $3.4 million and $1.2 million for the three months ended June 30, 2026 and June 30, 2025, respectively. See Note 7—Income Taxes in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for further information. Net loss. Net loss was $11.4 million and $4.7 million during the three months ended June 30, 2026, and June 30, 2025, respectively. Net loss during the three months ended June 30, 2026 compared to net loss for the three months ended June 30, 2025 was negatively impacted by the decrease in other income, the increase in interest expense, the decrease in investment income, the increase in rent expense, the increase in income tax provision and the increase in foreign currency translation rates, partially offset by the increase in attendance as a result of the popularity of new film releases compared to the prior year, decreases in depreciation and amortization and decreases in general and administrative expenses. ​ Theatrical Exhibition—U.S. Markets Revenues. Total revenues increased $144.4 million, or 13.0%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025. Admissions revenues increased $68.4 million, or 11.4%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to an increase in attendance of 12.0% from 46.9 million patrons to 52.5 million patrons, partially offset by a 0.5% decrease in average ticket price. The decrease in average ticket price was primarily due to decreases in attendance for 3D and IMAX screens and increased frequency for our A-list subscription members, partially offset by increases in attendance for PLF and XL screens and increased ticket prices. Attendance increased in U.S. markets due to the popularity of film product compared to the prior year. Food and beverage revenues increased $58.6 million, or 14.2%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to the increase in attendance and increase in food and beverage per patron. Food and beverage per patron increased 2.1% from $8.77 to $8.95 primarily due to an increase in average prices and the percentage of guests making transactions, partially offset by lower units per transaction by guests. 43 Table of Contents Total other theatre revenues increased $17.4 million, or 16.7%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to increases in income from ticket fees due to the increase in attendance, the number of guests paying ticket fees and increases in the price of ticket fees, and increases in advertising income. Operating costs and expenses. Operating costs and expenses increased $36.7 million, or 3.7%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025. Film exhibition costs increased $36.4 million, or 11.2%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to the increase in admissions revenue due to the factors discussed above, partially offset by the decrease in film exhibition cost percentage. As a percentage of admissions revenues, film exhibition costs were 54.3% for the three months ended June 30, 2026, compared to 54.4% for the three months ended June 30, 2025. Food and beverage costs increased $6.9 million, or 9.5%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025. The increase in food and beverage costs was primarily due to the increase in food and beverage revenues due to the factors discussed above, partially offset by the decrease in food and beverage cost percentage. As a percentage of food and beverage revenues, food and beverage costs were 17.0% for the three months ended June 30, 2026, compared to 17.7% for the three months ended June 30, 2025. Operating expense increased $2.1 million, or 0.6%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025. As a percentage of revenues, operating expense was 27.4% for the three months ended June 30, 2026, compared to 30.8% for the three months ended June 30, 2025. The decrease in operating expense as a percentage of revenues is primarily due to the operating leverage gained as attendance increases. Rent expense decreased $1.1 million, or 0.7%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to a decrease in average screens of 2.0%. Merger, acquisition, and other costs. Merger, acquisition, and other costs were $0.3 million during the three months ended June 30, 2026, compared to $0.1 million during the three months ended June 30, 2025. Other. Other general and administrative expense decreased $6.0 million, or 17.2%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to decreases in legal expenses due to insurance recoveries and decreases in stock-based compensation expense. Depreciation and amortization. Depreciation and amortization decreased $1.8 million, or 3.0%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to theatre closures and lower depreciation expense on theatres impaired during the year ended December 31, 2025. ​ Other expense (income). Other expense of $81.3 million during the three months ended June 30, 2026 was primarily due to $41.3 million of expense related to the increase in fair value of the derivative liability for the embedded derivative features in the New Exchangeable Notes, $33.0 million loss on extinguishment of the New Exchangeable Notes and $9.8 million of expense related to the increase in fair value of the derivative liability for the embedded derivative features in the Existing Exchangeable Notes, partially offset by $(3.4) million in equity in earnings related to non-consolidated entities. Other expense of $2.3 million during the three months ended June 30, 2025 was primarily due to $3.9 million of expense related to the increase in fair value of the derivative liability for the embedded conversion feature in the Existing Exchangeable Notes, partially offset by $(2.0) million in equity in earnings related to non-consolidated entities. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about the components of other expense (income). Interest expense. Interest expense increased $8.3 million to $121.3 million for the three months ended June 30, 2026 compared to $113.0 million during the three months ended June 30, 2025 primarily due to increased interest expense of $31.3 million on the New 2029 Notes issued on July 24, 2025 and $1.4 million on the New Exchangeable Notes issued on July 1, 2025, partially offset by declines in interest expense of $11.4 million on the Existing 7.5% Notes due to redemptions of $590.0 million aggregate principal amount on July 24, 2025, $7.8 million on the Existing Exchangeable Notes issued on July 22, 2024 due to redemptions of $337.4 million aggregate principal amount on July 24, 2025, $2.4 million on the Muvico Term Loans due to lower interest rates, $1.4 million on the Second Lien Notes due to redemptions of the remaining principal balances, $0.7 million on the Senior Subordinated Notes due 2026 due to redemptions of the remaining principal balances, and $0.5 million on the Senior Subordinated Notes due 2025 due to redemptions of the remaining principal balances. See Note 5—Corporate Borrowings and Finance Lease Liabilities in 44 Table of Contents the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about our indebtedness. Investment expense (income). Investment expense was $0.8 million for the three months ended June 30, 2026, compared to investment income of $(1.4) million for the three months ended June 30, 2025. Investment expense in the current year includes $1.5 million of unrealized losses on our investments in common shares in Hycroft, partially offset by interest income of $(0.7) million. Investment income in the prior year includes interest income of $(1.7) million, partially offset by $0.3 million of unrealized losses on our investments in common shares and warrants to purchase common shares in Hycroft. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about our investments in Hycroft. Income tax provision. The income tax provision was $1.7 million and $0.5 million for the three months ended June 30, 2026 and June 30, 2025, respectively. See Note 7—Income Taxes in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for further information. Net earnings. Net earnings were $18.5 million and $1.5 million during the three months ended June 30, 2026, and June 30, 2025, respectively. Net earnings during the three months ended June 30, 2026 compared to net earnings for the three months ended June 30, 2025 was positively impacted by the increase in attendance as a result of the popularity of new film releases compared to the prior year, decreases in rent expense, decreases in depreciation and amortization and decreases in general and administrative expenses, partially offset by the increase in other expense, the increase in interest expense, the decrease in investment income and the increase in income tax provision. ​ Theatrical Exhibition—International Markets Revenues. Total revenues increased $54.4 million, or 19.2%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025. Admissions revenues increased $32.1 million, or 19.6%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to an increase in attendance of 17.9% from 15.9 million patrons to 18.8 million patrons and a 1.5% increase in average ticket price. The increase in average ticket price was primarily due to increases in foreign currency translation rates. Attendance increased in International markets due to the popularity of film product compared to the prior year. Food and beverage revenues increased $17.9 million, or 20.3%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to the increase in attendance and increase in food and beverage per patron. Food and beverage per patron increased 2.2% from $5.54 to $5.66 primarily due to increases in foreign currency translation rates. Total other theatre revenues increased $4.4 million, or 13.9%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to increases in income from ticket fees due to the increase in attendance and increase in the number of guests paying ticket fees, increases in advertising income and increases in foreign currency translation rates. Operating costs and expenses. Operating costs and expenses increased $16.6 million, or 5.4%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025. Film exhibition costs increased $11.8 million, or 17.7%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to the increase in admissions revenues due to the factors discussed above, partially offset by the decrease in film exhibition cost percentage. As a percentage of admissions revenues, film exhibition costs were 39.9% for the three months ended June 30, 2026, compared to 40.6% for the three months ended June 30, 2025. Food and beverage costs increased $4.7 million, or 20.2%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025. The increase in food and beverage costs was primarily due to the increase in food and beverage revenues due to the factors discussed above. As a percentage of food and beverage revenues, food and beverage costs were 26.4% for the three months ended June 30, 2026 and the three months ended June 30, 2025. Operating expense decreased by $2.1 million, or 1.8%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025. The decrease in operating expense was primarily due to lower salaries and utilities expenses, partially offset by the increase in foreign currency translation rates and the increase in attendance. As a percentage of revenues, operating expense was 33.5% for the three months ended June 30, 2026, 45 Table of Contents compared to 40.6% for the three months ended June 30, 2025. The decrease in operating expense as a percentage of revenues is primarily due to the operating leverage gained as attendance increases. Rent expense increased $2.3 million, or 3.8%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to increases in foreign currency translation rates, partially offset by a decrease in average screens of 0.4%. Other. Other general and administrative expense decreased $0.2 million, or 0.9%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025. Depreciation and amortization. Depreciation and amortization increased $0.1 million, or 0.5%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to increases in foreign currency translation rates, partially offset by theatre closures and lower depreciation expense on theatres impaired during the year ended December 31, 2025. ​ Other expense (income). Other expense of $28.3 million during the three months ended June 30, 2026 was primarily due to $30.1 million loss on extinguishment of the Odeon Notes due 2027, partially offset by $(0.5) million in governmental assistance and $(0.4) million in foreign currency transaction gains. Other income of $(34.4) million during the three months ended June 30, 2025 was primarily due to $(23.9) million in foreign currency transaction gains and $(10.3) million of governmental assistance. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about the components of other expense (income). Interest expense. Interest expense decreased $1.9 million to $14.7 million for the three months ended June 30, 2026 compared to $16.6 million during the three months ended June 30, 2025 primarily due to a $2.2 million decline related to the refinancing of the Odeon Notes due 2027. See Note 5—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about our indebtedness. Investment income. Investment income was $(0.3) million for the three months ended June 30, 2026, compared to investment income of $0 million for the three months ended June 30, 2025. Investment income is comprised of interest income in the current period. Income tax provision. The income tax provision was $1.7 million and $0.7 million for the three months ended June 30, 2026 and June 30, 2025, respectively. See Note 7—Income Taxes in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for further information. Net loss. Net loss was $29.9 million and $6.2 million during the three months ended June 30, 2026, and June 30, 2025, respectively. Net loss during the three months ended June 30, 2026 compared to net loss for the three months ended June 30, 2025 was negatively impacted by the decrease in other income, the increase in rent expense, the increase in depreciation and amortization, the increase in income tax provision and the increase in foreign currency translation rates, partially offset by the increase in attendance as a result of the popularity of new film releases compared to the prior year, the decrease in interest expense, and the decrease in general and administrative expenses and the increase in investment income. Results of Operations—For the Six Months ended June 30, 2026, Compared to the Six Months ended June 30, 2025 Condensed Consolidated Results of Operations Revenues. Total revenues increased $381.7 million, or 16.9%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Admissions revenues increased $205.4 million, or 16.6%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to an increase in attendance of 13.6% from 104.7 million patrons to 118.9 million patrons and a 2.7% increase in average ticket price. The increase in average ticket price was primarily due to increased ticket prices for all formats, increases in attendance for PLF and XL screens and increases in foreign currency translation rates, partially offset by decreases in attendance for 3D and IMAX screens and increased frequency for our A-list subscription members. Attendance increased in U.S. and International markets due to the popularity of film product compared to the prior year. Food and beverage revenues increased $140.4 million, or 17.9%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to the increase in attendance and increase in food and 46 Table of Contents beverage per patron. Food and beverage per patron increased 3.9% from $7.48 to $7.77 primarily due to an increase in average prices, the percentage of guests making transactions, and increases in foreign currency translation rates, partially offset by lower units per transaction by guests. Total other theatre revenues increased $35.9 million, or 14.9%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to increases in income from ticket fees due to the increase in attendance, the number of guests paying ticket fees and increases in the price of ticket fees, increases in advertising income and increases in foreign currency translation rates, partially offset by decreases in income from expirations of package tickets and gift cards in our International markets. As a result of our Amended ESA, advertising income increased from the prior year by $5.2 million due to an increase in discount rates related to the significant financing component of the Amended ESA, partially offset by lower amortization of deferred revenues due to an increase in the term of the Amended ESA. See Note 3—Revenue Recognition in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about the Amended ESA. Operating costs and expenses. Operating costs and expenses increased $136.0 million, or 5.9%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Film exhibition costs increased $99.0 million, or 16.6%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to the increase in admissions revenue due to the factors discussed above. As a percentage of admissions revenues, film exhibition costs were 48.3% for the six months ended June 30, 2026 and the six months ended June 30, 2025. Food and beverage costs increased $20.8 million, or 13.6%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025. The increase in food and beverage costs was primarily due to the increase in food and beverage revenues due to the factors discussed above, partially offset by the decrease in food and beverage cost percentage. As a percentage of food and beverage revenues, food and beverage costs were 18.9% for the six months ended June 30, 2026, compared to 19.6% for the six months ended June 30, 2025. Operating expense increased by $14.1 million, or 1.7%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025. As a percentage of revenues, operating expense was 32.8% for the six months ended June 30, 2026, compared to 37.7% for the six months ended June 30, 2025. The decrease in operating expense as a percentage of revenues is primarily due to the operating leverage gained as attendance increases. Rent expense increased $7.2 million, or 1.6%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to increases in foreign currency translation rates, partially offset by a decrease in average screens of 1.4%. Merger, acquisition, and other costs. Merger, acquisition, and other costs were $1.4 million during the six months ended June 30, 2026, compared to $3.1 million during the six months ended June 30, 2025. The prior year expense relates to severance costs in U.S. markets. Other. Other general and administrative expense decreased $1.3 million, or 1.1%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025 primarily due to decreases in legal expenses due to insurance recoveries and stock-based compensation expense, partially offset by increases in foreign currency translation rates. Depreciation and amortization. Depreciation and amortization decreased $2.1 million, or 1.4%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to theatre closures and lower depreciation expense on theatres impaired during the year ended December 31, 2025, partially offset by increases in foreign currency translation rates. Other expense (income). Other expense of $57.2 million during the six months ended June 30, 2026 was primarily due to $33.0 million loss on extinguishment of the New Exchangeable Notes, $30.1 million loss on extinguishment of the Odeon Notes due 2027, $8.6 million in foreign currency transaction losses and $2.7 million of expense related to the increase in fair value of the derivative liability for the embedded derivative features in the Existing Exchangeable Notes, partially offset by $(11.1) million of income related to the increase in fair value of the derivative liability for the embedded derivative features in the New Exchangeable Notes, $(6.7) million in equity in earnings related to non-consolidated entities, and $(0.5) million in governmental assistance. Other income of $(90.9) million during the six months ended June 30, 2025 was primarily due to $(41.2) million of income related to the 47 Table of Contents decrease in fair value of the derivative liability for the embedded conversion feature in the Existing Exchangeable Notes, $(36.9) million in foreign currency transaction gains, $(10.5) million of governmental assistance, and $(2.9) million of equity in earnings of non-consolidated entities. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about the components of other expense (income). Interest expense. Interest expense increased $27.2 million to $275.9 million for the six months ended June 30, 2026 compared to $248.7 million during the six months ended June 30, 2025 primarily due to increased interest expense of $62.2 million on the New 2029 Notes issued on July 24, 2025, $9.4 million related to higher discount rates on the significant financing component of the Amended ESA and $5.0 million on the New Exchangeable Notes issued on July 1, 2025, partially offset by declines in interest expense of $22.8 million on the Existing 7.5% Notes due to redemptions of $590.0 million aggregate principal amount on July 24, 2025, $15.6 million on the Existing Exchangeable Notes issued on July 22, 2024 due to redemptions of $337.4 million aggregate principal amount on July 24, 2025, $4.5 million on the Muvico Term Loans due to lower interest rates, $2.9 million on the Second Lien Notes due to redemptions of the remaining principal balances, $1.8 million related to the refinancing of the Odeon Notes due 2027, $1.3 million on the Senior Subordinated Notes due 2026 due to redemptions of the remaining principal balances, and $1.2 million on the Senior Subordinated Notes due 2025 due to redemptions of the remaining principal balances. See Note 3—Revenue Recognition in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about the Amended ESA and Note 5—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about our indebtedness. Investment income. Investment income was $(17.8) million for the six months ended June 30, 2026, compared to investment income of $(7.1) million for the six months ended June 30, 2025. Investment income in the current year includes $(16.5) million of realized and unrealized gains on our investments in common shares in Hycroft, and interest income of $(1.3) million. Investment income in the prior year includes interest income of $(4.6) million and $(2.5) million of unrealized gains on our investments in common shares and warrants to purchase common shares in Hycroft. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about our investments in Hycroft. Income tax provision. The income tax provision was $5.6 million and $2.8 million for the six months ended June 30, 2026 and June 30, 2025, respectively. See Note 7—Income Taxes in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for further information. Net loss. Net loss was $128.5 million and $206.8 million during the six months ended June 30, 2026, and June 30, 2025, respectively. Net loss during the six months ended June 30, 2026 compared to net loss for the six months ended June 30, 2025 was positively impacted by the increase in attendance as a result of the popularity of new film releases compared to the prior year, decreases in depreciation and amortization, decreases in general and administrative expenses and the increase in investment income, partially offset by the decrease in other income, the increase in interest expense, the increase in rent expense, the increase in income tax provision and the increase in foreign currency translation rates. Theatrical Exhibition—U.S. Markets Revenues. Total revenues increased $268.2 million, or 15.5%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Admissions revenues increased $133.9 million, or 14.4%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to an increase in attendance of 12.8% from 73.8 million patrons to 83.3 million patrons and a 1.4% increase in average ticket price. The increase in average ticket price was primarily due to increased ticket prices for all formats and increases in attendance for PLF and XL screens, partially offset by decreases in attendance for 3D and IMAX screens and increased frequency for our A-list subscription members. Attendance increased in U.S. markets due to the popularity of film product compared to the prior year. Food and beverage revenues increased $100.4 million, or 16.0%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to the increase in attendance and increase in food and beverage per patron. Food and beverage per patron increased 2.8% from $8.52 to $8.76 primarily due to an increase in average prices and the percentage of guests making transactions, partially offset by lower units per transaction by guests. 48 Table of Contents Total other theatre revenues increased $33.9 million, or 19.6%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to increases in income from ticket fees due to the increase in attendance, the number of guests paying ticket fees and increases in the price of ticket fees and increases in advertising income. As a result of our Amended ESA, advertising income increased from the prior year by $5.2 million due to an increase in discount rates related to the significant financing component of the Amended ESA, partially offset by lower amortization of deferred revenues due to an increase in the term of the Amended ESA. See Note 3—Revenue Recognition in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about the Amended ESA. Operating costs and expenses. Operating costs and expenses increased $76.3 million, or 4.4%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Film exhibition costs increased $71.8 million, or 15.1%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to the increase in admissions revenue due to the factors discussed above and film rental terms. As a percentage of admissions revenues, film exhibition costs were 51.6% for the six months ended June 30, 2026, compared to 51.3% for the six months ended June 30, 2025. Food and beverage costs increased $10.2 million, or 9.0%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025. The increase in food and beverage costs was primarily due to the increase in food and beverage revenues due to the factors discussed above, partially offset by a decrease in food and beverage cost as a percentage of food and beverage revenues. As a percentage of food and beverage revenues, food and beverage costs were 17.0% for the six months ended June 30, 2026, compared to 18.1% for the six months ended June 30, 2025. Operating expense increased by $5.8 million, or 0.9%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025. As a percentage of revenues, operating expense was 31.9% for the six months ended June 30, 2026, compared to 36.5% for the six months ended June 30, 2025. The decrease in operating expense as a percentage of revenues is primarily due to the operating leverage gained as attendance increases. Rent expense decreased $1.3 million, or 0.4%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to a decrease in average screens of 1.8%. Merger, acquisition, and other costs. Merger, acquisition, and other costs were $1.2 million during the six months ended June 30, 2026, compared to $3.1 million during the six months ended June 30, 2025. The prior year expense relates to severance costs in U.S. markets. Other. Other general and administrative expense decreased $4.8 million, or 6.6%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to decreases in legal expenses due to insurance recoveries and stock-based compensation expense. Depreciation and amortization. Depreciation and amortization decreased $3.5 million, or 3.0%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to theatre closures and lower depreciation expense on theatres impaired during the year ended December 31, 2025. Other expense (income). Other expense of $19.8 million during the six months ended June 30, 2026 was primarily due to $33.0 million loss on extinguishment of the New Exchangeable Notes and $2.7 million of expense related to the increase in fair value of the derivative liability for the embedded derivative features in the Existing Exchangeable Notes, partially offset by $(11.1) million of income related to the increase in fair value of the derivative liability for the embedded derivative features in the New Exchangeable Notes, and $(6.0) million in equity in earnings related to non-consolidated entities. Other income of $(43.1) million during the six months ended June 30, 2025 was primarily due to $(41.2) million of income related to the decrease in fair value of the derivative liability for the embedded conversion feature in the Existing Exchangeable Notes and $(2.7) million of equity in earnings of non-consolidated entities. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about the components of other expense (income). Interest expense. Interest expense increased $28.5 million to $244.2 million for the six months ended June 30, 2026 compared to $215.7 million during the six months ended June 30, 2025 primarily due to increased interest expense of $62.2 million on the New 2029 Notes issued on July 24, 2025, $9.4 million related to higher discount rates on the significant financing component of the Amended ESA and $5.0 million on the New Exchangeable Notes issued 49 Table of Contents on July 1, 2025, partially offset by declines in interest expense of $22.8 million on the Existing 7.5% Notes due to redemptions of $590.0 million aggregate principal amount on July 24, 2025, $15.6 million on the Existing Exchangeable Notes issued on July 22, 2024 due to redemptions of $337.4 million aggregate principal amount on July 24, 2025, $4.5 million on the Muvico Term Loans due to lower interest rates, $2.9 million on the Second Lien Notes due to redemptions of the remaining principal balances, $1.3 million on the Senior Subordinated Notes due 2026 due to redemptions of the remaining principal balances, and $1.2 million on the Senior Subordinated Notes due 2025 due to redemptions of the remaining principal balances. See Note 3—Revenue Recognition in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about the Amended ESA and Note 5—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about our indebtedness. Investment income. Investment income was $(17.4) million for the six months ended June 30, 2026, compared to investment income of $(6.9) million for the six months ended June 30, 2025. Investment income in the current year includes $(16.5) million of realized and unrealized gains on our investments in common shares in Hycroft, and interest income of $(0.9) million. Investment income in the prior year includes interest income of $(4.4) million and $(2.5) million of unrealized gains on our investments in common shares and warrants to purchase common shares in Hycroft. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about our investments in Hycroft. Income tax provision. The income tax provision was $2.2 million and $1.4 million for the six months ended June 30, 2026 and June 30, 2025, respectively. See Note 7—Income Taxes in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for further information. Net loss. Net loss was $66.7 million and $176.9 million during the six months ended June 30, 2026, and June 30, 2025, respectively. Net loss during the six months ended June 30, 2026 compared to net loss for the six months ended June 30, 2025 was positively impacted by the increase in attendance as a result of the popularity of new film releases compared to the prior year, the decrease in rent expense, decreases in depreciation and amortization, decreases in general and administrative expenses and the increase in investment income, partially offset by the decrease in other income, the increase in interest expense, and the increase in income tax provision. Theatrical Exhibition—International Markets Revenues. Total revenues increased $113.5 million, or 21.4%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Admissions revenues increased $71.5 million, or 23.3%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to an increase in attendance of 15.3% from 30.9 million patrons to 35.7 million patrons and a 7.0% increase in average ticket price. The increase in average ticket price was primarily due to increases in foreign currency translation rates. Attendance increased in International markets due to the popularity of film product compared to the prior year. Food and beverage revenues increased $40.0 million, or 25.9%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to the increase in attendance and increase in food and beverage per patron. Food and beverage per patron increased 9.2% from $4.99 to $5.45 primarily due to the increase in foreign currency translation rates, an increase in average prices and the percentage of guests making transactions, partially offset by lower units per transaction by guests. Total other theatre revenues increased $2.0 million, or 2.9%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to, increases in income from ticket fees due to the increase in attendance and the number of guests paying ticket fees, increases in advertising income and increases in foreign currency translation rates, partially offset by decreases in income from expirations of package tickets and gift cards in our International markets. Operating costs and expenses. Operating costs and expenses increased $59.7 million, or 10.4%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Film exhibition costs increased $27.2 million, or 22.6%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to the increase in admissions revenues due to the factors discussed above. As a percentage of admissions revenues, film exhibition costs were 39.0% for the six months ended June 30, 2026, compared to 39.2% for the six months ended June 30, 2025. 50 Table of Contents Food and beverage costs increased $10.6 million, or 26.8%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025. The increase in food and beverage costs was primarily due to the increase in food and beverage revenues due to the factors discussed above. As a percentage of food and beverage revenues, food and beverage costs were 25.8% for the six months ended June 30, 2026, compared to 25.6% for the six months ended June 30, 2025. Operating expense increased by $8.3 million, or 3.8%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025. The increase in operating expense was primarily due to the increase in foreign currency translation rates and the increase in attendance. As a percentage of revenues, operating expense was 35.5% for the six months ended June 30, 2026, compared to 41.6% for the six months ended June 30, 2025. The decrease in operating expense as a percentage of revenues is primarily due to the operating leverage gained as attendance increases. Rent expense increased $8.5 million, or 7.4%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to increases in foreign currency translation rates, partially offset by a decrease in average screens of 0.4%. Merger, acquisition, and other costs. Merger, acquisition, and other costs were $0.2 million during the six months ended June 30, 2026, compared to $0 million during the six months ended June 30, 2025. Other. Other general and administrative expense increased $3.5 million, or 8.4%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025 primarily due to increases in foreign currency translation rates and increases in incentive bonus expense. Depreciation and amortization. Depreciation and amortization increased $1.4 million, or 3.9%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to increases in foreign currency translation rates, partially offset by theatre closures and lower depreciation expense on theatres impaired during the year ended December 31, 2025. Other expense (income). Other expense of $37.4 million during the six months ended June 30, 2026 was primarily due to $30.1 million loss on extinguishment of the Odeon Notes due 2027 and $8.6 million in foreign currency transaction losses, partially offset by governmental assistance of $(0.5) million. Other income of $(47.8) million during the six months ended June 30, 2025 was primarily due to $(36.9) million in foreign currency transaction gains and $(10.5) million of governmental assistance. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about the components of other expense (income). Interest expense. Interest expense decreased $1.3 million to $31.7 million for the six months ended June 30, 2026 compared to $33.0 million during the six months ended June 30, 2025 due to the refinancing of the Odeon Notes due 2027, partially offset by higher interest costs on capital and financing lease obligations. See Note 5—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about our indebtedness. Investment income. Investment income was $(0.4) million for the six months ended June 30, 2026, compared to investment income of $(0.2) million for the six months ended June 30, 2025. Investment income is comprised of interest income in the current and prior periods. Income tax provision. The income tax provision was $3.4 million and $1.4 million for the six months ended June 30, 2026 and June 30, 2025, respectively. See Note 7—Income Taxes in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for further information. Net loss. Net loss was $61.8 million and $29.9 million during the six months ended June 30, 2026, and June 30, 2025, respectively. Net loss during the six months ended June 30, 2026 compared to net loss for the six months ended June 30, 2025 was negatively impacted by the decrease in other income, the increase in rent expense, increases in depreciation and amortization, increases in general and administrative expenses, the increase in income tax provision and the increase in foreign currency translation rates, partially offset by the increase in attendance as a result of the popularity of new film releases compared to the prior year, decreases in interest expense and the increase in investment income. 51 Table of Contents ​ Adjusted EBITDA ​ We present Adjusted EBITDA as a supplemental measure of our performance. We define Adjusted EBITDA as net earnings (loss) plus (i) income tax provision (benefit), (ii) interest expense and (iii) depreciation and amortization, as further adjusted to eliminate the impact of certain items that we do not consider indicative of our ongoing operating performance and to include attributable EBITDA from equity investments in theatre operations in International markets. These further adjustments are itemized below. You are encouraged to evaluate these adjustments and the reasons we consider them appropriate for supplemental analysis. In evaluating Adjusted EBITDA, you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. Our definition of Adjusted EBITDA and adjustments made to net earnings (loss) to calculate it are broadly consistent with how Adjusted EBITDA is defined and calculated in our debt agreements. During the first quarter of 2026, we changed our definition of Adjusted EBITDA to adjust for net periodic pension cost. Net periodic pension cost is a recurring expense that includes several components such as service cost, interest cost, expected return on plan assets, amortization of prior service cost, and amortization of actuarial gains/losses. Additionally, we also include infrequent gains and losses from benefit curtailments and settlements of pension obligations in net periodic pension cost. We no longer believe that net periodic pension cost should be included in Adjusted EBITDA as the pension plans are frozen, service cost is zero, and the remaining components are not indicative of ongoing operating performance as they are not driven by current operating decisions and largely depend on actuarial assumptions. While not the basis for this change, the revised definition further aligns our definition of Adjusted EBITDA with the definition used in our debt agreements. The adjustment for net periodic pension cost is included in the caption titled “other expense (income)” in the condensed consolidated statement of operations and in the reconciliation of net loss to Adjusted EBITDA further below. See the components of other expense (income) table in Note 1—Basis of Presentation for net periodic pension cost recorded in each period presented. All comparative period information for Adjusted EBITDA has been re-cast to conform with the current definition. The impact of this change on previously reported Adjusted EBITDA for the three and six months ended June 30, 2025 was an improvement of $0.3 million and $0.6 million, respectively. The following tables set forth our Adjusted EBITDA by reportable operating segment and our reconciliation of Adjusted EBITDA: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended Adjusted EBITDA (In millions) ​ June 30, 2026 ​ ​ ​ June 30, 2025 ​ June 30, 2026 ​ ​ ​ June 30, 2025 U.S. markets ​ $ 285.6 ​ $ 181.3 ​ $ 307.5 ​ $ 124.2 International markets ​ ​ 35.8 ​ ​ 8.2 ​ ​ 52.2 ​ ​ 7.6 Total Adjusted EBITDA ​ $ 321.4 ​ $ 189.5 ​ $ 359.7 ​ $ 131.8 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended (In millions) ​ June 30, 2026 ​ June 30, 2025 ​ ​ ​ June 30, 2026 ​ June 30, 2025 Net loss ​ $ (11.4) ​ $ (4.7) ​ $ (128.5) ​ $ (206.8) Plus: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Income tax provision (1) ​ 3.4 ​ 1.2 ​ 5.6 ​ 2.8 Interest expense ​ 136.0 ​ 129.6 ​ 275.9 ​ 248.7 Depreciation and amortization ​ 76.1 ​ 77.8 ​ 151.8 ​ 153.9 Certain operating expense (2) ​ 2.3 ​ 2.6 ​ 2.0 ​ 5.4 Equity in earnings of non-consolidated entities (3) ​ (4.0) ​ (2.1) ​ (6.7) ​ (2.9) Attributable EBITDA (4) ​ ​ 0.6 ​ ​ 0.1 ​ ​ 0.8 ​ ​ 0.5 Investment expense (income) (5) ​ 0.5 ​ (1.4) ​ (17.8) ​ (7.1) Other expense (income) (6) ​ 114.3 ​ (19.7) ​ 64.6 ​ (77.5) Merger, acquisition and other costs (7) ​ 0.3 ​ 0.1 ​ 1.4 ​ 3.1 Stock-based compensation expense (8) ​ 3.3 ​ 6.0 ​ 10.6 ​ 11.7 Adjusted EBITDA ​ $ 321.4 ​ $ 189.5 ​ $ 359.7 ​ $ 131.8 ​ (1) For information regarding the income tax provision, see Note 7—Income Taxes in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q. 52 Table of Contents (2) Amounts represent preopening expense related to temporarily closed screens under renovation, theatre and other closure expense for the permanent closure of screens, disposition of assets, and other non-operating gains or losses included in operating expenses. We have excluded these items as they are non-cash in nature or related to theatres that are not open. (3) Equity in earnings of non-consolidated entities during the three months ended June 30, 2026 primarily consisted of equity in earnings from AC JV of $(3.3) million. Equity in earnings of non-consolidated entities during the three months ended June 30, 2025 primarily consisted of equity in earnings from AC JV of $(1.8) million. Equity in earnings of non-consolidated entities during the six months ended June 30, 2026 primarily consisted of equity in earnings from AC JV of $(5.7) million. Equity in earnings of non-consolidated entities during the six months ended June 30, 2025 primarily consisted of equity in earnings from AC JV of $(2.6) million. (4) Attributable EBITDA includes the EBITDA from equity investments in theatre operators in certain International markets. See below for a reconciliation of our equity in (earnings) of non-consolidated entities to attributable EBITDA. Because these equity investments are in theatre operators in regions where we hold a significant market share, we believe attributable EBITDA is more indicative of the performance of these equity investments and management uses this measure to monitor and evaluate these equity investments. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended (In millions) ​ June 30, 2026 ​ June 30, 2025 ​ ​ ​ June 30, 2026 ​ June 30, 2025 Equity in (earnings) of non-consolidated entities ​ $ (4.0) ​ $ (2.1) ​ $ (6.7) ​ $ (2.9) Less: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Equity in (earnings) of non-consolidated entities excluding International theatre joint ventures ​ ​ (3.5) ​ ​ (2.2) ​ ​ (6.2) ​ ​ (3.0) Equity in earnings (loss) of International theatre joint ventures ​ ​ 0.5 ​ ​ (0.1) ​ ​ 0.5 ​ ​ (0.1) Income tax benefit ​ ​ — ​ ​ (0.1) ​ ​ — ​ ​ (0.1) Investment income ​ ​ (0.1) ​ ​ — ​ ​ (0.1) ​ ​ — Interest expense ​ ​ — ​ ​ 0.1 ​ ​ — ​ ​ 0.1 Depreciation and amortization ​ ​ 0.2 ​ ​ 0.2 ​ ​ 0.4 ​ ​ 0.6 Attributable EBITDA ​ $ 0.6 ​ $ 0.1 ​ $ 0.8 ​ $ 0.5 ​ (5) Investment expense during the three months ended June 30, 2026 includes unrealized losses on our investment in Hycroft of $1.5 million, partially offset by interest income of $(1.0) million. Investment income during the three months ended June 30, 2025 included interest income of $(1.7) million, partially offset by unrealized losses on our investments in Hycroft of $0.3 million. Investment income during the six months ended June 30, 2026 includes realized and unrealized gains on our investments in Hycroft of $(16.5) million and interest income of $(1.3) million. Investment income during the six months ended June 30, 2025 included interest income of $(4.6) million and unrealized gains on our investments in Hycroft of $(2.5) million. (6) Other expense during the three months ended June 30, 2026 includes the increase in the fair value of the bifurcated embedded derivative in the New Exchangeable Notes of $41.3 million, the loss on extinguishment of the New Exchangeable Notes of $33.0 million, the loss on extinguishment of the Odeon Notes due 2027 of $30.1 million, the increase in the fair value of the bifurcated embedded derivative in the Existing Exchangeable Notes of $9.8 million and net periodic pension cost of $0.5 million, partially offset by foreign currency transaction gains of $(0.4) million. Other income during the three months ended June 30, 2025 included foreign currency transaction gains of $(23.9) million, partially offset by an increase in the fair value of the bifurcated embedded derivative in the Existing Exchangeable Notes of $3.9 million and $0.3 million of net periodic pension cost. Other expense during the six months ended June 30, 2026 includes the loss on extinguishment of the New Exchangeable Notes of $33.0 million, the loss on extinguishment of the Odeon Notes due 2027 of $30.1 million, foreign currency transaction losses of $8.6 million, the increase in the fair value of the bifurcated embedded derivative in the Existing Exchangeable Notes of $2.7 million, net periodic pension cost of $1.0 million and debt modification third party fees of $0.3 million, partially offset by the decrease in the fair value 53 Table of Contents of the bifurcated embedded derivative in the New Exchangeable Notes of $(11.1) million. Other income during the six months ended June 30, 2025 included a decrease in the fair value of the bifurcated embedded derivative in the Existing Exchangeable Notes of $(41.2) million and foreign currency transaction gains of $(36.9) million, partially offset by $0.6 million of net periodic pension cost. (7) Merger, acquisition and other costs are excluded as they are non-operating in nature. (8) Non-cash expense included in general and administrative: other. Adjusted EBITDA is a non-GAAP financial measure commonly used in our industry and should not be construed as an alternative to net earnings (loss) as an indicator of operating performance (as determined in accordance with U.S. GAAP). Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. We have included Adjusted EBITDA because we believe it provides management and investors with additional information to measure our performance and estimate our value. Adjusted EBITDA has important limitations as an analytical tool, and you should not consider it in isolation, or as a substitute for analysis of our results as reported under U.S. GAAP. For example, Adjusted EBITDA: ● does not reflect our capital expenditures, future requirements for capital expenditures or contractual commitments; ● does not reflect changes in, or cash requirements for, our working capital needs; ● does not reflect the significant interest expenses, or the cash requirements necessary to service interest or principal payments on our debt; ● excludes income tax payments that represent a reduction in cash available to us; and ● does not reflect any cash requirements for the assets being depreciated and amortized that may have to be replaced in the future. During the three months ended June 30, 2026, Adjusted EBITDA in the U.S. markets was $285.6 million compared to $181.3 million during the three months ended June 30, 2025. The year-over-year increase was primarily driven by an increase in attendance due to the popularity of film releases compared to the prior year and an increase in food and beverage per patron, partially offset by lower average ticket price. During the three months ended June 30, 2026, Adjusted EBITDA in the International markets was $35.8 million compared to $8.2 million during the three months ended June 30, 2025. The year-over-year increase was primarily driven by an increase in attendance due to the popularity of film releases compared to the prior year and the increase in foreign currency translation rates, partially offset by lower amounts of governmental assistance. During the three months ended June 30, 2026, Adjusted EBITDA in the U.S. markets and International markets was $321.4 million compared to $189.5 million during the three months ended June 30, 2025, driven by the aforementioned factors impacting Adjusted EBITDA. During the six months ended June 30, 2026, Adjusted EBITDA in the U.S. markets was $307.5 million compared to $124.2 million during the six months ended June 30, 2025. The year-over-year increase was primarily driven by an increase in attendance due to the popularity of film releases compared to the prior year, an increase in average ticket price and food and beverage per patron and an increase in advertising income in other revenues related to an increase in discount rates for the significant financing component of the Amended ESA. During the six months ended June 30, 2026, Adjusted EBITDA in the International markets was $52.2 million compared to $7.6 million during the six months ended June 30, 2025. The year-over-year increase was primarily driven by an increase in attendance due to the popularity of film releases compared to the prior year, an increase in average ticket price and food and beverage per patron and the increase in foreign currency translation rates, partially offset by lower amounts of governmental assistance and decreases in income from expirations of package tickets and gift cards. During the six months ended June 30, 2026, Adjusted EBITDA in the U.S. markets and International markets was $359.7 million compared to $131.8 million during the six months ended June 30, 2025, driven by the aforementioned factors impacting Adjusted EBITDA. LIQUIDITY AND CAPITAL RESOURCES ​ Our consolidated revenues are primarily collected in cash, principally through admissions and food and beverage sales. We have an operating “float” which partially finances our operations and which generally permits us to maintain a smaller amount of working capital capacity. This float exists because admissions revenues are received in 54 Table of Contents cash, while exhibition costs (primarily film rentals) are ordinarily paid to distributors from 14 to 49 days following receipt of admissions revenues. Film distributors generally release the films which they anticipate will be the most successful during the summer and year-end holiday seasons. Consequently, we typically generate higher revenues during such periods and experience higher working capital requirements following such periods. We had working capital deficit (excluding restricted cash) as of June 30, 2026, and December 31, 2025 of $(901.0) million and $(1,090.6) million, respectively. As of June 30, 2026 and December 31, 2025, working capital included operating lease liabilities of $560.4 million and $560.0 million, respectively, and deferred revenues of $452.6 million and $465.5 million, respectively. As of June 30, 2026, we had cash and cash equivalents of $778.4 million. During the six months ended June 30, 2026, we enhanced liquidity through equity issuances. See Note 6—Stockholders’ Deficit in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for further information. We expect, from time to time, to continue to seek to retire or purchase our outstanding debt through cash purchases and/or exchanges for equity or debt, in open-market purchases, privately negotiated transactions or otherwise. We continuously monitor the capital markets and our capital structure, and may, from time to time, seek to refinance, amend or otherwise restructure our outstanding debt on an opportunistic basis. Such repurchases, refinancings, amendments, restructurings or exchanges, if any, will be upon such terms and at such prices as we may determine, and will depend on prevailing market conditions, our liquidity requirements, the availability of authorized share capital, contractual restrictions and other factors. The amounts involved may be material and, to the extent equity is used, dilutive. Odeon Credit Agreement On April 17, 2026, Odeon Finco, a wholly-owned direct subsidiary of OCGL and an indirect subsidiary of Holdings, entered into the Odeon Credit Agreement, by and among Odeon Finco, as borrower, OCGL, as the company, the lenders party thereto and U.S. Bank Trust Company, National Association, as administrative agent and security agent, pursuant to which Odeon Finco borrowed $425.0 million of Odeon Term Loans due 2031. The Odeon Term Loans due 2031 bear interest at a fixed 10.50% interest rate and are subject to amortization of principal, payable in quarterly installments on the fifteenth day of each April, July, October, and January (commencing July 15, 2026), equal to 1.00% per annum. The proceeds from the Odeon Term Loans due 2031 and approximately $38.2 million of cash from the balance sheet were used to fund the Odeon Notes Redemption of Odeon Finco’s outstanding Odeon Notes due 2027 and to pay related fees, costs, premiums and expenses, including approximately $23.5 million of interest due on the Odeon Notes due 2027. In connection with the Odeon Notes Redemption, the Odeon Notes due 2027 have been delisted from the Official List of The International Stock Exchange. See Note 5—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for further information. New Exchangeable Notes Voluntary Exchange On May 4 and May 11, 2026, the Exchanging Noteholders delivered Notices of Voluntary Exchange to Muvico and GLAS Trust Company LLC, as exchange agent, to exchange all $155,845,562 aggregate principal amount of New Exchangeable Notes outstanding for shares of Common Stock, pursuant to the terms of the Indenture. The Company settled the Exchange by issuing an aggregate of 142,102,295 shares of Common Stock to the Exchanging Noteholders (including shares issued in respect of the Exchange Adjustment Consideration (as defined in the Indenture) and $0.9 million accrued and unpaid interest). As a result of the Exchange, all remaining New Exchangeable Notes were cancelled in accordance with the Indenture. 2027 Notes Redemption Notice Concurrently with the completion of the Offering, on June 24, 2026, we delivered the Notice to holders of our $125.5 million aggregate principal amount of Senior Subordinated Notes due 2027 to redeem the Senior Subordinated Notes due 2027 in full at a redemption price equal to 100.000% of the principal amount of the Senior Subordinated Notes due 2027, plus accrued and unpaid interest, if any, to July 24, 2026, the redemption date. 55 Table of Contents Liquidity Requirements We believe our existing cash and cash equivalents, together with cash generated from operations, will be sufficient to fund our operations and satisfy our obligations currently and through the next twelve months. Our historical cash burn rates are not sustainable long-term. Based on our current cost structure, in order to achieve sustainable annual net positive cash flows from operating activities, we believe that revenues will need to be at least in line with pre-COVID-19 revenues. The Company has achieved net positive cash flows from operating activities for the six months ended June 30, 2026. Until such time as we are able to achieve sustainable annual net positive cash flows from operating activities, it is difficult to estimate our future cash burn rates and liquidity requirements. Depending on our assumptions regarding the timing and ability to achieve levels of revenue, the estimates of the required liquidity vary significantly. There can be no assurance that the revenues, costs, attendance levels and other assumptions used to estimate our liquidity requirements and future cash burn rates will be correct, and our ability to be predictive is uncertain due to our limited ability to predict studio film release dates, the overall production and theatrical release levels and success of individual titles. Further, there can be no assurances that we will be successful in generating the additional liquidity necessary to meet our obligations beyond twelve months from the issuance of this Quarterly Report on terms acceptable to us or at all. The following is a summary of our net cash flows for the six months ended June 30, 2026 and June 30, 2025: ​ ​ ​ ​ ​ ​ ​ (in millions) ​ June 30, 2026 ​ June 30, 2025 Operating activities ​ $ 106.9 ​ $ (231.6) Investing activities ​ ​ (59.6) ​ ​ (95.6) Financing activities ​ ​ 297.6 ​ ​ 109.1 ​ Cash Flows from Operating Activities ​ Net cash provided by (used in) operating activities improved by $338.5 million primarily due to increases in attendance, increases in average ticket price, increases in food and beverage per patron, increases in advertising revenue, and an increase cash provided by working capital. The increase in cash provided by working capital was primarily driven by the float from film rental payments, which typically are paid to distributors 20 to 45 days following the receipt of admissions revenue. The box office in the second quarter of 2026 outperformed the box office in the second quarter of 2025. Cash Flows from Investing Activities ​ Net cash used in investing activities decreased by $36.0 million primarily due to proceeds from the sale of part of our investment in Hycroft and increases in proceeds from sales of long-term assets. We fund the costs of constructing, maintaining and remodeling our theatres through existing cash balances, cash generated from operations, lease incentives, or capital raised, as necessary. We generally lease our theatres pursuant to long-term, non-cancelable operating leases, which may require the developer who owns the property, to help fund our construction costs by offering lease incentives. We estimate that our capital expenditures, net of lease incentives, will be approximately $200.0 million to $235.0 million for the year ending December 31, 2026 to maintain and enhance operations. Cash Flows from Financing Activities Net cash provided by financing activities increased by $188.5 million primarily due to increased proceeds from equity issuances and decreases in cash used for principal payments of the Senior Subordinated Notes due 2025, partially offset by an increase in cash used to pay deferred financing costs. Covenant Compliance As of June 30, 2026, we believe that we were in full compliance with all agreements, including related covenants, governing our outstanding debt. 56 Table of Contents Formation of Unrestricted Subsidiaries On July 22, 2024, Multi-Cinema, a Missouri corporation and a direct subsidiary of Holdings, assigned or transferred the net assets (“Theatre Net Assets”) of 175 theatres and transferred a 100% interest in certain intellectual property assets to its direct subsidiary Centertainment Development, LLC (“Centertainment”), and the Theatre Net Assets were in turn transferred to Centertainment’s direct wholly-owned subsidiary Muvico. Theatre Net Assets include lease contracts and theatre property, including furniture, fixtures, plant and equipment, and other working capital items associated directly with the theatre locations. At the same time, Muvico licensed the intellectual property back to Multi-Cinema for its continued use in the operation of its retained theatres and entered into a management agreement for Multi-Cinema to operate the theatres transferred to Muvico. Muvico and Centertainment (collectively, the “Muvico Group”) are unrestricted subsidiaries under the indenture governing Holdings’ 7.5% First Lien Senior Secured Notes (the “Existing 7.5% Notes”). Unrestricted Subsidiaries’ Financial Information and Operating Metrics Pursuant to the indenture governing Holdings’ Existing 7.5% Notes and the Muvico Credit Agreement governing Holdings’ and Muvico’s new term loans maturing in 2029 (the “Muvico Term Loans”), we are presenting the following financial information and operating metrics for the Muvico Group separately from Holdings and its restricted subsidiaries (the “Restricted Subsidiaries” and collectively with Holdings, the “AMC Group”). AMC Theatres of UK Limited, which is an unrestricted subsidiary under the indenture governing Holdings’ Existing 7.5% Notes, has been included with the Restricted Subsidiaries for the purposes of the following presentation of financial information and operating metrics (this subsidiary is individually immaterial). The financial information presented for AMC Group and Muvico Group is presented on a standalone basis with discrete identification of the assets, liabilities, revenues and expenses associated with the Theatre Net Assets that were transferred to Muvico. Intercompany transactions between entities within the AMC Group or within the Muvico Group have been eliminated. Certain entities within the AMC Group and within the Muvico Group are parties to intercompany management, licensing, and debt agreements with each other. These transactions are reflected discretely within the columnar presentation below and are properly eliminated upon consolidation. The financial information is also prepared using the historical cost carrying values of Holdings, the top parent entity. Holdings and Muvico are co-borrowers and jointly and severally liable for the Muvico Term Loans. Pursuant to ASC 405-40, we have allocated fifty percent (50%) of the liabilities, interest expense and cash flows each to Muvico and Holdings, respectively. The basis of this allocation is the amount we expect each party to pay. ​ 57 Table of Contents ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2026 ​ ​ AMCEH & ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Restricted ​ Muvico Group ​ ​ ​ ​ ​ ​ ​ Subsidiaries/AMC ​ Unrestricted ​ ​ ​ ​ ​ ​ Group (1) ​ Subsidiaries ​ Eliminations ​ Consolidated (In millions) ​ ​ ​ (unaudited) ​ (unaudited) ​ (unaudited) ​ (unaudited) Revenues ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Admissions ​ $ 600.5 ​ $ 262.6 ​ $ — ​ $ 863.1 Food and beverage ​ ​ 430.9 ​ ​ 145.2 ​ ​ — ​ ​ 576.1 Other theatre (3) ​ ​ 133.2 ​ ​ 33.8 ​ ​ (9.5) ​ ​ 157.5 Total revenues ​ ​ 1,164.6 ​ ​ 441.6 ​ ​ (9.5) ​ ​ 1,596.7 Operating costs and expenses ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Film exhibition costs ​ ​ 298.5 ​ ​ 141.8 ​ ​ — ​ ​ 440.3 Food and beverage costs ​ ​ 84.1 ​ ​ 23.6 ​ ​ — ​ ​ 107.7 Operating expense, excluding depreciation and amortization below ​ ​ 345.2 ​ ​ 113.2 ​ ​ — ​ ​ 458.4 Rent ​ ​ 167.9 ​ ​ 55.9 ​ ​ — ​ ​ 223.8 General and administrative: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Merger, acquisition and other costs ​ ​ 0.3 ​ ​ — ​ ​ — ​ ​ 0.3 Other, excluding depreciation and amortization below (3) ​ ​ 56.2 ​ ​ 5.3 ​ ​ (9.5) ​ ​ 52.0 Depreciation and amortization ​ ​ 58.0 ​ ​ 18.1 ​ ​ — ​ ​ 76.1 Operating costs and expenses ​ ​ 1,010.2 ​ ​ 357.9 ​ ​ (9.5) ​ ​ 1,358.6 Operating income ​ ​ 154.4 ​ ​ 83.7 ​ ​ — ​ ​ 238.1 Other expense, net: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other expense ​ ​ 25.4 ​ ​ 84.2 ​ ​ — ​ ​ 109.6 Interest expense: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Corporate borrowings ​ ​ 51.1 ​ ​ 64.8 ​ ​ — ​ ​ 115.9 Finance lease obligations ​ ​ 1.7 ​ ​ — ​ ​ — ​ ​ 1.7 Non-cash NCM exhibitor services agreement ​ ​ 18.4 ​ ​ — ​ ​ — ​ ​ 18.4 Intercompany interest expense (income), net ​ ​ (0.5) ​ ​ 0.5 ​ ​ — ​ ​ — Investment expense (income) ​ ​ 0.8 ​ ​ (0.3) ​ ​ — ​ ​ 0.5 Total other expense, net ​ ​ 96.9 ​ ​ 149.2 ​ ​ — ​ ​ 246.1 Earnings (loss) before income taxes ​ ​ 57.5 ​ ​ (65.5) ​ ​ — ​ ​ (8.0) Income tax provision (2) ​ ​ 3.4 ​ ​ — ​ ​ — ​ ​ 3.4 Net earnings (loss) ​ $ 54.1 ​ $ (65.5) ​ $ — ​ $ (11.4) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2026 ​ ​ AMCEH & ​ ​ ​ ​ ​ ​ ​ ​ Restricted ​ Muvico Group ​ ​ ​ ​ ​ Subsidiaries/AMC ​ Unrestricted ​ ​ ​ ​ Group (1) ​ Subsidiaries ​ Consolidated (In millions) ​ (unaudited) ​ (unaudited) ​ (unaudited) Net earnings (loss) ​ $ 54.1 ​ $ (65.5) ​ $ (11.4) Other comprehensive loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ Unrealized foreign currency translation adjustments ​ ​ (16.2) ​ ​ — ​ ​ (16.2) Net pension gain arising during the period ​ ​ 0.2 ​ ​ — ​ ​ 0.2 Other comprehensive loss ​ ​ (16.0) ​ ​ — ​ ​ (16.0) Total comprehensive income (loss) ​ $ 38.1 ​ $ (65.5) ​ $ (27.4) ​ (1) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indenture governing Existing 7.5% Notes and (ii) AMC Group under the Muvico Credit Agreement. Transactions between Holdings and its restricted subsidiaries have been eliminated. (2) Muvico is a disregarded entity for federal and state income tax purposes with all tax expense and deferred taxes recorded at the AMC Group level. (3) Includes intercompany management fee revenues of $5.3 million recorded by AMCEH & Restricted Subsidiaries/AMC Group and intercompany license fee revenues of $4.2 million recorded by Muvico Group 58 Table of Contents Unrestricted Subsidiaries. Corresponding amounts of expense are included in general and administrative: other for Muvico Group Unrestricted Subsidiaries and AMCEH & Restricted Subsidiaries/AMC Group. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2026 ​ ​ AMCEH & ​ ​ ​ ​ ​ ​ ​ ​ Restricted ​ Muvico Group ​ ​ ​ ​ ​ Subsidiaries/AMC ​ Unrestricted ​ ​ ​ ​ Group (3) ​ Subsidiaries ​ Consolidated Key operating metrics: ​ (unaudited) ​ (unaudited) ​ (unaudited) Average ticket price $ 11.69 ​ $ 13.19 ​ $ 12.11 Attendance (in thousands) (1) ​ 51,385 ​ ​ 19,905 ​ ​ 71,290 Number of screens operated (2) ​ ​ 7,315 ​ ​ 2,215 ​ ​ 9,530 Number of theatres operated (2) ​ ​ 673 ​ ​ 172 ​ ​ 845 Adjusted EBITDA (4) $ 219.6 ​ $ 101.8 ​ $ 321.4 ​ (1) Includes consolidated theatres only and excludes screens offline due to construction. (2) The screens and theatres of the Muvico Group are operated by Multi-Cinema pursuant to the management agreement. (3) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indenture governing the Existing 7.5% Notes and (ii) AMC Group under the Muvico Credit Agreement. (4) Below is a reconciliation of net loss to Adjusted EBITDA for AMCEH & Restricted Subsidiaries/AMC Group and Muvico Group. The reconciling items below have the same definitions and are of the same nature as the reconciling items presented previously in Management’s Discussion and Analysis section of this Form 10-Q. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2026 ​ ​ AMCEH & ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Restricted ​ Muvico Group ​ ​ ​ ​ ​ ​ ​ ​ Subsidiaries/AMC ​ Unrestricted ​ ​ ​ ​ ​ ​ ​ Group (1) ​ Subsidiaries ​ Eliminations ​ Consolidated (In millions) ​ (unaudited) ​ (unaudited) ​ (unaudited) ​ (unaudited) Net earnings (loss) ​ $ 54.1 ​ $ (65.5) ​ $ — ​ $ (11.4) Plus: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Income tax provision ​ 3.4 ​ — ​ ​ — ​ 3.4 Interest expense ​ 71.2 ​ 65.3 ​ ​ (0.5) ​ 136.0 Depreciation and amortization ​ 58.0 ​ 18.1 ​ ​ — ​ 76.1 Certain operating expense ​ 2.3 ​ — ​ ​ — ​ 2.3 Equity in earnings of non-consolidated entities ​ (4.0) ​ — ​ ​ — ​ (4.0) Attributable EBITDA ​ ​ 0.6 ​ ​ — ​ ​ — ​ ​ 0.6 Investment expense (income) ​ 0.3 ​ (0.3) ​ ​ 0.5 ​ 0.5 Other expense ​ 30.1 ​ 84.2 ​ ​ — ​ 114.3 Merger, acquisition and other costs ​ 0.3 ​ — ​ ​ — ​ 0.3 Stock-based compensation expense ​ 3.3 ​ — ​ ​ — ​ 3.3 Adjusted EBITDA ​ $ 219.6 ​ $ 101.8 ​ $ — ​ $ 321.4 ​ (1) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indenture governing the Existing 7.5% Notes and (ii) AMC Group under the Muvico Credit Agreement. ​ 59 Table of Contents ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2026 ​ ​ AMCEH & ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Restricted ​ Muvico Group ​ ​ ​ ​ ​ ​ ​ Subsidiaries/AMC ​ Unrestricted ​ ​ ​ ​ ​ ​ Group (1) ​ Subsidiaries ​ Eliminations ​ Consolidated (In millions) ​ ​ ​ (unaudited) ​ (unaudited) ​ (unaudited) ​ (unaudited) Revenues ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Admissions ​ $ 1,023.9 ​ $ 417.6 ​ $ — ​ $ 1,441.5 Food and beverage ​ ​ 700.0 ​ ​ 223.4 ​ ​ — ​ ​ 923.4 Other theatre (3) ​ ​ 238.3 ​ ​ 53.1 ​ ​ (14.2) ​ ​ 277.2 Total revenues ​ ​ 1,962.2 ​ ​ 694.1 ​ ​ (14.2) ​ ​ 2,642.1 Operating costs and expenses ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Film exhibition costs ​ ​ 482.3 ​ ​ 213.6 ​ ​ — ​ ​ 695.9 Food and beverage costs ​ ​ 137.5 ​ ​ 36.6 ​ ​ — ​ ​ 174.1 Operating expense, excluding depreciation and amortization below ​ ​ 658.5 ​ ​ 207.2 ​ ​ — ​ ​ 865.7 Rent ​ ​ 336.7 ​ ​ 111.2 ​ ​ — ​ ​ 447.9 General and administrative: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Merger, acquisition and other costs ​ ​ 1.4 ​ ​ — ​ ​ — ​ ​ 1.4 Other, excluding depreciation and amortization below (3) ​ ​ 119.5 ​ ​ 7.6 ​ ​ (14.2) ​ ​ 112.9 Depreciation and amortization ​ ​ 115.6 ​ ​ 36.2 ​ ​ — ​ ​ 151.8 Operating costs and expenses ​ ​ 1,851.5 ​ ​ 612.4 ​ ​ (14.2) ​ ​ 2,449.7 Operating income ​ ​ 110.7 ​ ​ 81.7 ​ ​ — ​ ​ 192.4 Other expense, net: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other expense ​ ​ 32.2 ​ ​ 25.0 ​ ​ — ​ ​ 57.2 Interest expense: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Corporate borrowings ​ ​ 104.6 ​ ​ 131.2 ​ ​ — ​ ​ 235.8 Finance lease obligations ​ ​ 3.2 ​ ​ — ​ ​ — ​ ​ 3.2 Non-cash NCM exhibitor services agreement ​ ​ 36.9 ​ ​ — ​ ​ — ​ ​ 36.9 Intercompany interest expense (income), net ​ ​ 1.2 ​ ​ (1.2) ​ ​ — ​ ​ — Investment income ​ ​ (17.4) ​ ​ (0.4) ​ ​ — ​ ​ (17.8) Total other expense, net ​ ​ 160.7 ​ ​ 154.6 ​ ​ — ​ ​ 315.3 Loss before income taxes ​ ​ (50.0) ​ ​ (72.9) ​ ​ — ​ ​ (122.9) Income tax provision (2) ​ ​ 5.6 ​ ​ — ​ ​ — ​ ​ 5.6 Net loss ​ $ (55.6) ​ $ (72.9) ​ $ — ​ $ (128.5) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2026 ​ ​ AMCEH & ​ ​ ​ ​ ​ ​ ​ ​ Restricted ​ Muvico Group ​ ​ ​ ​ ​ Subsidiaries/AMC ​ Unrestricted ​ ​ ​ ​ Group (1) ​ Subsidiaries ​ Consolidated (In millions) ​ (unaudited) ​ (unaudited) ​ (unaudited) Net loss ​ $ (55.6) ​ $ (72.9) ​ $ (128.5) Other comprehensive loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ Unrealized foreign currency translation adjustments ​ ​ (31.7) ​ ​ — ​ ​ (31.7) Net pension gain arising during the period ​ ​ 0.2 ​ ​ — ​ ​ 0.2 Other comprehensive loss ​ ​ (31.5) ​ ​ — ​ ​ (31.5) Total comprehensive loss ​ $ (87.1) ​ $ (72.9) ​ $ (160.0) ​ (1) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indenture governing the Existing 7.5% Notes and (ii) AMC Group under the Muvico Credit Agreement. Transactions between Holdings and its restricted subsidiaries have been eliminated. (2) Muvico is a disregarded entity for federal and state income tax purposes with all tax expense and deferred taxes recorded at the AMC Group level. 60 Table of Contents (3) Includes intercompany management fee revenues of $7.6 million recorded by AMCEH & Restricted Subsidiaries/AMC Group and intercompany license fee revenues of $6.6 million recorded by Muvico Group Unrestricted Subsidiaries. Corresponding amounts of expense are included in general and administrative: other for Muvico Group Unrestricted Subsidiaries and AMCEH & Restricted Subsidiaries/AMC Group. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2026 ​ ​ AMCEH & ​ ​ ​ ​ ​ ​ ​ ​ Restricted ​ Muvico Group ​ ​ ​ ​ ​ Subsidiaries/AMC ​ Unrestricted ​ ​ ​ ​ Group (3) ​ Subsidiaries ​ Consolidated Key operating metrics: ​ (unaudited) ​ (unaudited) ​ (unaudited) Average ticket price $ 11.70 ​ $ 13.30 ​ $ 12.12 Attendance (in thousands) (1) ​ ​ 87,502 ​ ​ 31,410 ​ ​ 118,912 Number of screens operated (2) ​ 7,315 ​ ​ 2,215 ​ ​ 9,530 Number of theatres operated (2) ​ 673 ​ ​ 172 ​ ​ 845 Adjusted EBITDA (4) $ 241.7 ​ $ 118.0 ​ $ 359.7 ​ (1) Includes consolidated theatres only and excludes screens offline due to construction. (2) The screens and theatres of the Muvico Group are operated by Multi-Cinema pursuant to the management agreement. (3) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indenture governing the Existing 7.5% Notes and (ii) AMC Group under the Muvico Credit Agreement. (4) Below is a reconciliation of net loss to Adjusted EBITDA for AMCEH & Restricted Subsidiaries/AMC Group and Muvico Group. The reconciling items below have the same definitions and are of the same nature as the reconciling items presented previously in Management’s Discussion and Analysis section of this Form 10-Q. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2026 ​ ​ AMCEH & ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Restricted ​ Muvico Group ​ ​ ​ ​ ​ ​ ​ ​ Subsidiaries/AMC ​ Unrestricted ​ ​ ​ ​ ​ ​ ​ Group (1) ​ Subsidiaries ​ Eliminations ​ Consolidated (In millions) ​ (unaudited) ​ (unaudited) ​ (unaudited) ​ (unaudited) Net loss ​ $ (55.6) ​ $ (72.9) ​ $ — ​ $ (128.5) Plus: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Income tax provision ​ 5.6 ​ — ​ ​ — ​ 5.6 Interest expense ​ 145.9 ​ 131.2 ​ ​ (1.2) ​ 275.9 Depreciation and amortization ​ 115.6 ​ 36.2 ​ ​ — ​ 151.8 Certain operating expense ​ 1.9 ​ 0.1 ​ ​ — ​ 2.0 Equity in earnings of non-consolidated entities ​ (6.7) ​ — ​ ​ — ​ (6.7) Attributable EBITDA ​ ​ 0.8 ​ ​ — ​ ​ — ​ ​ 0.8 Investment income ​ (17.4) ​ (1.6) ​ ​ 1.2 ​ (17.8) Other expense, net ​ 39.6 ​ 25.0 ​ ​ — ​ 64.6 Merger, acquisition and other costs ​ 1.4 ​ — ​ ​ — ​ 1.4 Stock-based compensation expense ​ 10.6 ​ — ​ ​ — ​ 10.6 Adjusted EBITDA ​ $ 241.7 ​ $ 118.0 ​ $ — ​ $ 359.7 ​ (1) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indenture governing the Existing 7.5% Notes and (ii) AMC Group under the Muvico Credit Agreement. 61 Table of Contents ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2026 ​ ​ AMCEH & ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Restricted ​ Muvico Group ​ ​ ​ ​ ​ ​ ​ Subsidiaries/AMC ​ Unrestricted ​ ​ ​ ​ ​ ​ Group (3) ​ Subsidiaries ​ Eliminations ​ Consolidated (In millions, except share data) ​ (unaudited) ​ (unaudited) ​ (unaudited) ​ (unaudited) ASSETS ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents (1) ​ $ 352.9 ​ $ 425.5 ​ $ — ​ $ 778.4 Restricted cash ​ ​ 41.1 ​ ​ — ​ ​ — ​ ​ 41.1 Receivables, net ​ ​ 121.4 ​ ​ 4.2 ​ ​ — ​ ​ 125.6 Other current assets ​ ​ 76.9 ​ ​ 16.2 ​ ​ — ​ ​ 93.1 Total current assets ​ ​ 592.3 ​ ​ 445.9 ​ ​ — ​ ​ 1,038.2 Property, net ​ ​ 990.7 ​ ​ 324.6 ​ ​ — ​ ​ 1,315.3 Operating lease right-of-use assets, net ​ ​ 2,260.2 ​ ​ 704.0 ​ ​ — ​ ​ 2,964.2 Intangible assets, net ​ ​ 41.6 ​ ​ 104.4 ​ ​ — ​ ​ 146.0 Goodwill ​ ​ 2,377.6 ​ ​ — ​ ​ — ​ ​ 2,377.6 Other long-term assets ​ ​ 201.7 ​ ​ 0.6 ​ ​ — ​ ​ 202.3 Intercompany receivables (2) ​ ​ — ​ ​ 1,943.2 ​ ​ (1,943.2) ​ ​ — Investment in subsidiary ​ ​ 607.1 ​ ​ — ​ ​ (607.1) ​ ​ — Total assets ​ $ 7,071.2 ​ $ 3,522.7 ​ $ (2,550.3) ​ $ 8,043.6 LIABILITIES AND STOCKHOLDERS’ DEFICIT ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Current liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accounts payable ​ $ 327.9 ​ $ 68.8 ​ $ — ​ $ 396.7 Accrued expenses and other liabilities ​ ​ 295.1 ​ ​ 37.0 ​ ​ — ​ ​ 332.1 Deferred revenues and income ​ ​ 440.2 ​ ​ 12.4 ​ ​ — ​ ​ 452.6 Current maturities of corporate borrowings ​ ​ 139.0 ​ ​ 9.9 ​ ​ — ​ ​ 148.9 Current maturities of finance lease liabilities ​ ​ 7.4 ​ ​ — ​ ​ — ​ ​ 7.4 Current maturities of operating lease liabilities ​ ​ 413.6 ​ ​ 146.8 ​ ​ — ​ ​ 560.4 Total current liabilities ​ ​ 1,623.2 ​ ​ 274.9 ​ ​ — ​ ​ 1,898.1 Corporate borrowings ​ ​ 1,708.5 ​ ​ 1,994.2 ​ ​ — ​ ​ 3,702.7 Finance lease liabilities ​ ​ 45.2 ​ ​ — ​ ​ — ​ ​ 45.2 Operating lease liabilities ​ ​ 2,605.8 ​ ​ 644.8 ​ ​ — ​ ​ 3,250.6 Exhibitor services agreement ​ ​ 455.9 ​ ​ — ​ ​ — ​ ​ 455.9 Deferred tax liability, net (4) ​ ​ 36.1 ​ ​ — ​ ​ — ​ ​ 36.1 Intercompany payables (2) ​ ​ 1,943.2 ​ ​ — ​ ​ (1,943.2) ​ ​ — Other long-term liabilities ​ ​ 106.0 ​ ​ 1.7 ​ ​ — ​ ​ 107.7 Total liabilities ​ ​ 8,523.9 ​ ​ 2,915.6 ​ ​ (1,943.2) ​ ​ 9,496.3 Commitments and contingencies ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Stockholders’ or member's equity (deficit): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Preferred stock ​ ​ — ​ ​ — ​ ​ — ​ ​ — Class A common stock ​ ​ 8.9 ​ ​ — ​ ​ — ​ ​ 8.9 Additional paid-in capital ​ ​ 7,719.8 ​ ​ 819.6 ​ ​ (819.6) ​ ​ 7,719.8 Accumulated other comprehensive loss ​ ​ (73.7) ​ ​ — ​ ​ — ​ ​ (73.7) Accumulated deficit ​ ​ (9,107.7) ​ ​ (212.5) ​ ​ 212.5 ​ ​ (9,107.7) Total stockholders' or member's equity (deficit) ​ ​ (1,452.7) ​ ​ 607.1 ​ ​ (607.1) ​ ​ (1,452.7) Total liabilities and stockholders’ or member's equity (deficit) ​ $ 7,071.2 ​ $ 3,522.7 ​ $ (2,550.3) ​ $ 8,043.6 (1) The cash held in bank accounts differs from the book balance due to deposits in transit, payments in transit, and certain cash equivalents. (2) Intercompany receivables (payables) includes intercompany loans, fees receivable/payable pursuant to the management agreement and intellectual property license agreement, the intercompany receivable/payable created by allocating the Muvico Term Loans borrowings between Holdings and Muvico, and other intercompany balances created as a result of the 2025 Refinancing Transactions and 2024 Refinancing Transactions. (3) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indenture governing the Existing 7.5% Notes and (ii) AMC Group under the Muvico Credit Agreement. 62 Table of Contents (4) Muvico is a disregarded entity for federal and state income tax purposes with all tax expense and deferred taxes recorded at the AMC Group level. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2026 ​ ​ AMCEH & ​ ​ ​ ​ ​ ​ ​ ​ Restricted ​ Muvico Group ​ ​ ​ ​ ​ Subsidiaries/AMC ​ Unrestricted ​ ​ ​ ​ Group (1) ​ Subsidiaries ​ Consolidated (In millions) ​ (unaudited) ​ (unaudited) ​ (unaudited) Net loss ​ $ (55.6) ​ $ (72.9) ​ $ (128.5) Adjustments to reconcile net loss to net cash provided by (used in) operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and amortization ​ ​ 115.6 ​ ​ 36.2 ​ ​ 151.8 Loss on extinguishment of debt ​ ​ 30.1 ​ ​ 33.0 ​ ​ 63.1 Gain on derivatives ​ ​ — ​ ​ (8.4) ​ ​ (8.4) Deferred income taxes ​ ​ 0.4 ​ ​ — ​ ​ 0.4 Gain on investments in Hycroft ​ ​ (16.5) ​ ​ — ​ ​ (16.5) Amortization of net discount on corporate borrowings to interest expense ​ ​ 4.9 ​ ​ 0.6 ​ ​ 5.5 Amortization of deferred financing costs to interest expense ​ ​ 4.0 ​ ​ 6.1 ​ ​ 10.1 PIK interest expense ​ ​ — ​ ​ 30.9 ​ ​ 30.9 Non-cash portion of stock-based compensation ​ ​ 10.6 ​ ​ — ​ ​ 10.6 Equity in earnings from non-consolidated entities, net of distributions ​ ​ (4.0) ​ ​ — ​ ​ (4.0) Lease incentives ​ ​ 24.6 ​ ​ — ​ ​ 24.6 Non-cash rent benefit ​ ​ (50.6) ​ ​ (7.9) ​ ​ (58.5) Net periodic pension cost ​ ​ 1.0 ​ ​ — ​ ​ 1.0 Change in assets and liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Receivables ​ ​ 24.0 ​ ​ 1.6 ​ ​ 25.6 Other assets ​ ​ (21.0) ​ ​ 20.1 ​ ​ (0.9) Accounts payable ​ ​ (8.6) ​ ​ 26.8 ​ ​ 18.2 Accrued expenses and other liabilities ​ ​ (34.9) ​ ​ 8.7 ​ ​ (26.2) Intercompany receivables and payables ​ ​ (254.3) ​ ​ 254.3 ​ ​ — Other, net ​ ​ 7.2 ​ ​ 0.9 ​ ​ 8.1 Net cash provided by (used in) operating activities ​ ​ (223.1) ​ ​ 330.0 ​ ​ 106.9 Cash flows from investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures ​ ​ (71.1) ​ ​ (20.4) ​ ​ (91.5) Proceeds from disposition of long-term assets ​ ​ 2.2 ​ ​ — ​ ​ 2.2 Proceeds from sale of Hycroft ​ ​ 29.7 ​ ​ — ​ ​ 29.7 Net cash used in investing activities ​ ​ (39.2) ​ ​ (20.4) ​ ​ (59.6) Cash flows from financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Net proceeds from equity issuances ​ ​ 334.6 ​ ​ — ​ ​ 334.6 Proceeds from issuance of Odeon Term Loans due 2031 ​ ​ 416.5 ​ ​ — ​ ​ 416.5 Principal payments under Odeon Senior Secured Notes due 2027 ​ ​ (400.0) ​ ​ — ​ ​ (400.0) Premium paid to extinguish Odeon Senior Secured Notes due 2027 ​ ​ (12.8) ​ ​ — ​ ​ (12.8) Principal payments under finance lease obligations ​ ​ (3.0) ​ ​ — ​ ​ (3.0) Scheduled principal payments under term loan borrowings ​ ​ (5.0) ​ ​ (5.0) ​ ​ (10.0) Cash used to pay deferred financing costs ​ ​ (19.8) ​ ​ (4.2) ​ ​ (24.0) Taxes paid for restricted unit withholdings ​ ​ (3.7) ​ ​ — ​ ​ (3.7) Proceeds (payments) of intercompany loans ​ ​ 53.6 ​ ​ (53.6) ​ ​ — Net cash provided by (used in) financing activities ​ ​ 360.4 ​ ​ (62.8) ​ ​ 297.6 Effect of exchange rate changes on cash and cash equivalents and restricted cash ​ ​ (2.7) ​ ​ — ​ ​ (2.7) Net increase in cash and cash equivalents and restricted cash ​ ​ 95.4 ​ ​ 246.8 ​ ​ 342.2 Cash and cash equivalents and restricted cash at beginning of period ​ ​ 298.6 ​ ​ 178.7 ​ ​ 477.3 Cash and cash equivalents and restricted cash at end of period ​ $ 394.0 ​ $ 425.5 ​ $ 819.5 ​ (1) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indenture governing the Existing 7.5% Notes and (ii) AMC Group under the Muvico Credit Agreement. ​ ​ ​ ​ ​ ​ 63 Table of Contents